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Abstract  
Recently, many “molecular profiling” projects have yielded vast amounts of genetic, 
epigenetic, transcription, protein expression, metabolic and drug response data for 
cancerous tumours, healthy tissues, and cell lines.  
 
We aim to facilitate a multi-scale understanding of these high-dimensional biological 
data and the complexity of the relationships between the different data types taken 
from human tumours. Further, we intend to identify molecular disease subtypes of 
various cancers, uncover the subtype-specific drug targets and identify sets of 
therapeutic molecules that could potentially be used to inhibit these targets. 
  
We collected data from over 20 publicly available resources. We then leverage 
integrative computational systems analyses, network analyses and machine learning, 
to gain insights into the pathophysiology of pancreatic cancer and 32 other human 
cancer types.  
  
Here, we uncover aberrations in multiple cell signalling and metabolic pathways that 
implicate regulatory kinases and the Warburg effect as the likely drivers of the distinct 
molecular signatures of three established pancreatic cancer subtypes. Then, we apply 
an integrative clustering method to four different types of molecular data to reveal that 
pancreatic tumours can be segregated into two distinct subtypes. We define sets of 
proteins, mRNAs, miRNAs and DNA methylation patterns that could serve as 
biomarkers to accurately differentiate between the two pancreatic cancer subtypes. 
Then we confirm the biological relevance of the identified biomarkers by showing that 
these can be used together with pattern-recognition algorithms to infer the drug 
sensitivity of pancreatic cancer cell lines accurately.  
 
Further, we evaluate the alterations of metabolic pathway genes across 32 human 
cancers. We find that while alterations of metabolic genes are pervasive across all 
human cancers, the extent of these gene alterations varies between them. Based on 
these gene alterations, we define two distinct cancer supertypes that tend to be 
associated with different clinical outcomes and show that these supertypes are likely 
to respond differently to anticancer drugs.  
 
Overall, we show that the time has already arrived where we can mine available data 
resources to potentially elicit more precise and personalised cancer therapies that 
would yield better clinical outcomes at a much lower cost than is currently being 
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Chapter 1 : General Introduction  
 
If I had to nominate one key to success, it’s a focus on, well, everything…  
— Andrew Fitzgibbon 
 
1.1 Introduction  
Recent advances in various high-throughput experimental technologies and 
associated computational analysis techniques, have provided modern medicine with 
powerful tools for devising novel strategies to treat some of the world’s most 
burdensome diseases. These advances have enabled the emergence of systems 
biology: a holistic, global, interdisciplinary and integrative approach to understanding 
the molecular processes that manifest as living organisms.  Systems biology has, in 
turn, prompted the rise to systems medicine: a science focusing on the accurate 
modelling of complex diseases [1]. Systems biology approaches are illuminating both 
how the molecular components of cells interact with one another to form functional 
units within healthy cells, and the specific perturbances within and between these units 
that yield diseased cellular states [2].  
We now live in an era where a constellation of amazing technologies is allowing us to 
construct, disturb, and observe biological model systems in the laboratory with 
unprecedented fidelity and throughput [3–7]. Over the last few years large-scale 
“molecular profiling” projects applying these technologies have yielded vast amounts 
of genetic, epigenetic, transcription, protein expression, metabolic and drug response 
data for cancerous tumours, diseased tissues, and cell lines [8,9]. Concurrently, 
comprehensive information has been gathered on the properties of thousands of 
cellular proteins, their functions, their interaction partners and the signalling or 
metabolic pathways within which they function [10,11]. While the accessibility of these 
“big data” has been enabled by the development and population of various large 
databases and data repositories, various statistical tools implemented in an array of 
different data analysis software have also been devised to extract actionable insights 
from the data. Although these developments are promising to transform the treatment 
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of all human diseases – from communicable infections to genetic disorders and 
cancers – the unprecedented complexity and scale of the accumulating data is 
presenting formidable analytical challenges [12].  
 
The extraction of meaningful information on cellular processes from large scale 
genetic (or genomic), epigenetic (or epigenomic), transcription (or transcriptomic), 
protein expression (or proteomic), metabolism (or metabolomic), requires the 
application of innovative data mining and data integration approaches [13]. Further, 
cellular components in general form complex biological systems containing huge 
numbers of interconnected agents [14–16]. Such systems are dynamic, and frequently 
have “emergent” properties that cannot be entirely understood even given a 
comprehensive understanding of each of their individual parts.  
 
Concretely, complex systems can be perceived as scale-free networks wherein the 
molecular components within the systems (for example proteins) are represented as 
nodes and the possibility of interactions between the components (for example 
protein-protein binding) are represented by edges between nodes [17,18]. These 
networks are arranged in a hierarchical manner, whereby sub-complex systems form 
modules of the higher level complex systems generating what is known as a 
hierarchical network [14,19]. Network representations of complex systems has 
revolutionised many physics, chemistry, and mathematics research fields.  Besides 
also having useful applications in ecology and evolutionary biology research, network 
representations of complex systems are also crucial in systems biology and cell 
signalling research. Casting the complexity of molecular cellular systems as networks 
can be instrumental in understanding how these systems are organised and regulated. 
When, for example, the networks in question represent systems with regulatory and/or 
signalling functions, the nodes with the highest numbers of edges may represent 
“central” proteins, or inflexions that could be targeted to disrupt/modify cell 
signalling/regulation [20,21].   
 
To facilitate a multiscale understanding of high-dimensional biological data and the 
complexity of the relationships between different data types (such as between 
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genomic, transcriptomic and proteomic data types), there is presently a concerted 
drive towards  the development of novel data integration techniques [2,22–24]. In most 
cases, these computational techniques aim to leverage an understanding of the 
functional cellular components in physiology and disease using prior-knowledge 
network representations of biological systems (such as protein-protein interaction or 
gene regulatory networks) in conjunction with statistical and machine learning 
methods to analyse different data types derived from the same sets of biological 
specimens. This has led to a paradigm shift; from testing a small number of 
hypotheses that are defined well before data is even collected, to using the data to 
develop testable hypothesis based on observed connections between potential 
causes and effects that we never thought existed.  
To facilitate the generation of hypothesis, data from most large-scale molecular 
profiling projects are freely accessible, searchable, and downloadable. Many of these 
datasets (see table 1-1 for some examples) contain multiple sources of information on 
the same sets of biological samples with, for example, individual specimens having 
combinations of associated epidemiological and/or clinical data, genome sequence 
data, methylation data, RNA transcription and/or protein expression data and drug 
response data. 
Table 1-1: Big data and biological knowledge resources for bioinformatics and systems biology 
# Resource Available Data Web Portal  Statistics 
1 The Cancer Genome 
Atlas [8] 
Multi-molecular data profiling from 
patients with clinical information 
https://portal.gdc.canc
er.gov/ 
33,605 donors and 
374,699 data files 





15,513 donors and 
231,751 data files  
3 Gene Expression 
Omnibus [25] 





and 4,348 datasets  
4 Expression Atlas [26] Gene expression across species 





Expression Portal [27] 
Resource of tissue-specific gene 




6 Cancer Cell Line 
Encyclopaedia [6] 
Detailed genetic and 
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7 Genomics of Drug 
Sensitivity in Cancer 
[5] 






8 Cancer Target 
Discovery and 
Development [28] 
Data generated from different 
types of approaches, e.g. 






1,004 drugs and 35 
cancers 
9 Library of Integrated 
Cellular-based 
Signature [3,29] 
Gene expression and functional 




1,127 cells treated 
with 41847 small 
molecules 
10 BioGrid [30] Genetic and protein interaction 
data 
https://thebiogrid.org/ Over 1,670,000 
interactions 
11 KEGG pathways [11] 
Molecular interactions, reaction 




533 pathways and 
29,545,122 
genes 






and 10,883 human 
proteins 
13 Sider 4.1 Side Effect 
Resources [32]  
Information on marketed 
medicines and their recorded 
adverse drug reactions 
http://sideeffects.embl.
de/ 
1430 drug and 5868 
Side effects 
14 DrugBank [33] Detailed drug data with 





and 5,177 proteins 
15 PharmaGKB [34] Curated knowledge about the 
impact of genetic 
variations on drug response 
https://www.pharmgkb
.org/ 
656 drugs, 136 
pathways and 132 
clinical guidelines 
16 ClinicalTrail.gov [35] Database of privately and publicly 





17 Universal Protein 
Resource [36] 
A comprehensive resource of 





18 Encyclopedia of DNA 
Elements [37,38] 
A comprehensive list of functional 
elements in the human genome, 
including elements that act at the 
protein and RNA levels, and 
regulatory elements that control 
cells and circumstances in which 




experimental data  
  5 
19 The Gene Ontology 
Resource [39] 
Comprehensive information on 












Data on spontaneous, induced, 
and genetically-engineered 








21 The Human 
Phenotype Ontology 
[41] 
Data on phenotypic abnormalities 
encountered in human disease 
https://hpo.jax.org/app
/ 
Over 13,000 terms 
and over 156,000 
annotations to 
hereditary disease 
22 Online Mendelian 
Inheritance in Man 
[42,43] 






23 Proteomic Database 
[44] 
Database for exploration and 
analysis of human proteome data 
https://www.proteomic
sdb.org/#overview 
15,721 proteins and 
43,237,800 spectra 
24 Allen Brain Atlas [45] Data and web application to 
explore the biological complexity 
of the mammalian brain 
http://portal.brain-
map.org/ 









searching, and filtering of 
information on drug-gene 
interactions and the druggable 
genome 
http://www.dgidb.org/ 40,000 genes and 
10,000 drugs 
involved in over 
15,000 drug-gene 
interactions 
26 Catalogue of Somatic 
Mutations in Cancer 
[47,48] 
World's largest and most 
comprehensive resource for 
exploring the impact of somatic 







27 Project Achilles [4,49] Genome-scale RNAi and 
CRISPR-Cas9 genetic 
perturbation to silence or 
knockout individual genes and 





1,627 cell lines 
across 38 primary 
diseases 
 
28 Human Proteome 
Map [49] 
Integrated massive peptide 
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158 cancer studies 
and 40,199 
samples 
30 The National Center 
for Biotechnology 
Information [13] 





31 Human Protein 
Reference Database 
[51] 
Integrated information pertaining 
to domain architecture, post-
translational modifications, 
interaction networks and disease 
association for each protein 






32 Human Protein 
Atlas [52,53] 
Expression and localization of 








33 Strings [54] Protein-protein interaction 












protein interactions mined from 





proteins and their 
verified interactions 
35 CORUM [56] The comprehensive resource of 































Curated compilation of high-
quality protein-protein interactions 
from 8 interactome resources 
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The data from each of these resources can often be integrated or augmented with 
data either from other resources or from additional laboratory experiments.  By 
enabling a more holistic multi-dimensional view of human diseases, integrative 
analysis of multiple data types from these various freely accessible resources can be 
used to fast-track the development of new therapies by focusing more traditional 
biomedical research and development activities on the in vitro validation of 
computationally predicted drug targets and therapeutic molecules (Figure 1-1). 
 
Figure 1-1: Overall representation of the data integration challenge in computational systems biology: 
The resources that contain similar datasets are shown in groups. The large-scale datasets from each 
resource can be individually analysed or integrated with data from other resources that provide 
complimentary information on genes, proteins, drugs, pathways or protein-protein interactions, and 




This integrative “data-first” approach has already yielded solutions to numerous 
problems than would have taken decades longer to solve using more traditional 

















D g Ge e
I e ac
C D2
























  8 
molecules [61–63], correctly predicting drug targets [64–67], and correctly predicting 
the responses of tumours to anticancer drugs  [68–74].  
 
Given that many of the currently available datasets have a strong cancer focus, much 
of the activity in this burgeoning research area is on curing cancer.  Although, 
integrative data-first approaches have yielded small molecule inhibitors for targeted-
therapies of tumours that have improved the survival of patients afflicted with many 
forms of cancers [75–78], there remain  many other forms of cancers for which such 
approaches have not yet yielded effective therapies [79–81]. For example, pancreatic 
cancers, triple negative breast cancers and lung cancers remain very difficult to treat 
because they have variable responses to available anticancer drugs. However, the 
underlying molecular causes of these variable responses should themselves be 
discernible using integrative data-first approaches and, once the correct subtypes of 
the cancer in question have been determined it should be possible to both identify 
prospective subtype-specific drug targets for each of these, and identify sets of 
therapeutic molecules that could potentially be used to inhibit these targets.  
Given the perpetually increasing cost and difficulty of developing new drugs using 
traditional reductionist approaches [82–84], it would be completely untenable to 
consider the development of therapeutics that would only be useable in, for example, 
small subsets of cancer patients.  The strength of computational systems approaches 
is that, when they are applied to molecular data (i.e. genomic sequence, RNA 
transcription or protein expression data) for even just a single tumour, it is plausible 
that they could both identify the metabolic aberrations within the cells of that tumour, 
and indicate the chemical compound(s) that should be used to most effectively and 
specifically treat that tumour. In such cases the cost of drug development would simply 
be the cost of obtaining the pertinent metabolic data: a cost that, due to economy of 
scales and continuing technological innovation, is anticipated to progressively 
decrease.   
At the moment, however, publicly available data for patients with tumours displaying 
similar molecular profiles is enough for us to begin using computational approaches 
to find the best treatment options for some of the less common and/or more variable 
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cancers.  Despite the promise of integrative data-first approaches in the development 
of therapeutics, using publicly available data to accurately identify appropriate drug 
targets that could enable the treatment of specific cancer variants remains non-trivial. 
Besides the computational complexity of both characterizing the different subtypes of 
cancer that can arise within a given tissue, and then identifying suitable therapeutics 
for these cancer subtypes, the effective deployment of these therapeutics will require 
(potentially costly) molecular profiling and categorization of patient tumours.  
Fortunately, once we have accurately identified the different subtypes of any particular 
cancer, the molecular profiling and classification of new tumours need not involve the 
extensive determination of the tumours’ genomes, transcriptomes and proteomes. 
Rather, the identification of genetic polymorphisms in a few “marker” genes or the 
determination of a small number of marker mRNA transcription levels and/or marker 
protein expression levels may suffice to accurately determine which drugs a tumour 
will be most sensitive to. In this regard machine learning strategies (both supervised 
and unsupervised) have proven to be highly effective for the identification of small 
numbers of marker genes, transcripts and proteins that can be used to accurately 
classify tumours.  These methods have additionally been useful for pinpointing both 
the molecular dependencies responsible for the varied responses of different cancer 
subtype to different drugs, and, in so doing, identifying the specific therapeutic 
compounds that could best be deployed to treat these cancer subtypes  [22,24,85].  
In this thesis, we collect and mine data from over 20 publicly available resources. We 
then leverage integrative computational systems analyses, network analyses and 
machine learning, to gain insights into the pathology of pancreatic cancer subtypes. 
Using these contemporary analytical approaches, we also evaluate the alterations of 
metabolic pathway genes across 32 human cancers and the impact that these genetic 
alterations have on both treatment outcomes and the responses of tumours to different 
anticancer drugs. We show that using these big data resources we can: (1) accelerate 
the discovery of drug targets by identifying cellular signalling network nodes that can 
be used to disrupt the disease process, and (2) predict either patient-specific or cancer 
subtype specific drug candidates. The overarching message of this thesis is that the 
time has already arrived where we are able to leverage available data resources to 
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potentially elicit more precise and personalised cancer therapies that would yield 
better clinical outcomes at a much lower cost than is currently being achieved.   
1.2 Thesis Organization  
This thesis is organized into five chapters. Chapters 2-4 are manuscripts that have 
either been published in a peer reviewed journal or have been submitted to one. 
Chapter 5 is a general discussion on the significance and impact of the studies 
presented in Chapters 2-4.  
Chapter 1 
We provide an introduction to big data and data integration in the context of 
computational systems biology. 
 
Chapter 2 
We present results published in the paper entitled “Integrative landscape of 
dysregulated signalling pathways of clinically distinct pancreatic cancer subtypes”. 
Here, we used publicly available pancreatic cancer datasets from The Cancer 
Genome Atlas (including transcriptome profiles, gene copy number alterations, 
mutation profiles, proteome profiles and data on disease outcomes) to provide, for the 
first time, a comprehensive landscape of pathway alterations that are associated with 
pancreatic cancer. Using transcriptome data, we identified three pancreatic cancer 
subtypes that displayed distinctive survival outcomes. Further, using various pathway 
and network analysis approaches of these data, we uncovered aberrations in multiple 
cell signalling and metabolic pathways that implicate regulatory kinases and the 
Warburg effect as the likely drivers of the distinct molecular signatures of the different 
pancreatic cancer subtypes. Through integrative analysis of mRNA expression 
profiles, gene mutations, gene copy number alterations, proteome datasets, and prior 
knowledge, we found that, to varying extents in the three pancreatic cancer subtypes, 
hyperactivation of the PI3K-mTOR and MAPK pathways, and dysregulation of p53 and 
cell cycle control processes, are apparently the drivers of pancreatic cancer 
progression. 
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Chapter 3 
We addressed the challenge of inconsistent classifications of pancreatic cancer 
patient tumours when the tumours are subtyped using different types of molecular data 
using an integrative clustering method called Similarity Network Fusion. Using 
targeted proteomics and other molecular data compiled by The Cancer Genome Atlas 
we revealed that pancreatic tumours can be broadly segregated into two distinct 
subtypes. Besides being associated with substantially different clinical outcomes, 
tumours belonging to each of these subtypes also display notable differences in 
diverse signalling pathways and biological processes. At the proteome level, we show 
that tumours belonging to the less severe subtype are characterised by aberrant 
mTOR signalling, whereas those belonging to the more severe subtype are 
characterised by disruptions in SMAD and cell cycle-related processes. We use 
machine learning algorithms to define sets of proteins, mRNAs, miRNAs and DNA 
methylation patterns that could serve as biomarkers to accurately differentiate 
between the two pancreatic cancer subtypes. Lastly, we confirm the biological 
relevance of the identified biomarkers by showing that these can be used together with 
pattern-recognition algorithms to accurately infer the drug sensitivity of pancreatic 
cancer cell lines. Our study shows that integrative profiling of multiple data types 
enables a biological and clinical representation of pancreatic cancer that is 
comprehensive enough to provide a foundation for future therapeutic strategies.  
 
Chapter 4 
We evaluate the “The Frequency of Metabolic Genes Alterations Impacts the Clinical 
Aggressiveness and Drug Response of 32 Human Cancers”.  Here, using genomics 
data from the Cancer Genome Atlas for 10,528 tumours of 32 different cancer types, 
we characterise the alterations of genes involved in various metabolic pathways 
across all human cancers. We find that while mutations and copy number variations 
of metabolic genes are pervasive across all human cancers, the extent of these gene 
alterations varies between them. We identify that the most common alterations are to 
genes involved in lipid, carbohydrate and amino acid metabolism. Based on the 
frequencies of metabolic pathway gene alterations, we further find that there are two 
distinct cancer supertypes that tend to be associated with different clinical outcomes. 
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By utilising the known dose-response profiles of 825 human cancer cell lines from the 
Genomics of Drug Sensitivity in Cancer dataset, we infer that cancers belonging to 
these supertypes are likely to respond differently to various anticancer drugs. Further, 
we show that for each of the 32 human cancer types, the altered genes involved in 
particular metabolic pathways are associated with observed variations in the drug 
responses of tumours to many different anticancer drugs. Collectively our analyses 
define the foundational metabolic features of different cancer supertypes and subtypes 




We provide a conclusion to this thesis and recommendations for future work in big 
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Chapter 2 : Integrative Landscape of Dysregulated Signalling 
Pathways of Clinically Distinct Pancreatic Cancer Subtypes 
 
This section is a reformatting of a paper published in Oncotarget [86]: 
https://doi.org/10.18632/oncotarget.25632 
 
Musalula Sinkala, Nicola Mulder, Darren Martin 
2.1 Introduction 
Pancreatic cancer is the most lethal form of cancer. It has an extremely poor prognosis 
with less than 20% of patients surviving for more than one year following diagnosis 
[87,88]. Factors contributing to reduced survival rates are the difficulty of diagnosing 
the disease during its early stages, the rapid progression of tumours with few specific 
associated symptoms, and the diversity of responses that different forms of pancreatic 
cancer have to anticancer drugs [89,90]. Despite progress having been made towards 
understanding the histological phenotypes and molecular mechanisms at play, 
positive responses to conventional chemotherapy regimens have remained 
infrequent, and the overall survival rates of patients have not substantially improved 
[91].  
 
A significant challenge to achieving better treatment outcomes has been the 
heterogeneity of pancreatic cancers. Underlying this heterogeneity is the vast array of 
somatic mutations that are acquired during oncogenesis, and the varied effects that 
these mutations have on cell signalling pathways [92,93]. Recent analyses of genomic 
sequence datasets from patients with advanced disease have identified potential 
activating mutations, many of which occur in genes encoding proteins that might be 
suitable drug targets [94,95]. In this regard the discovery of mutation hot-spots in 
various signalling kinases has already prompted the development of highly selective 
kinase inhibitors that are capable of specifically killing pancreatic cancer cells. 
Although the antitumor activities of some of these kinase inhibitors have been strong, 
they have rarely been long-lasting, with the targeted cancers frequently developing 
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resistance [93]. There is, therefore, a pressing need to identify additional potential drug 
targets amongst the dysregulated signalling and metabolic pathway components that 
differentiate pancreatic cancer subtypes.  Used in conjunction with kinase-inhibitors, 
novel drugs targeting these pathway components could yield pancreatic cancer 
therapies with longer lasting effectiveness. 
Aiding in the discovery of novel drug targets has been the use of next-generation 
sequencing based analytical methods that simultaneously identify mutations in 
sequences and quantify the expression of all the cellular genes that might have an 
impact on cancer progression. In this regard, the Cancer Genome Atlas (TCGA) 
project, has performed a systematic genomic, transcriptomic and proteomic 
characterisation of matched healthy and cancerous tissue samples from thousands of 
individuals afflicted with a variety of cancers [96].  This data, together with matched 
clinical information is publicly available and includes data for 185 pancreatic cancer 
patients. Combining data on transcription levels, gene mutations, copy number 
alteration, protein expression levels and clinical information, the intention of such 
datasets is to uncover causal relationships between specific genetic and/or cellular 
aberrations and the onset of disease [97].  
Recent genomic studies using such datasets have both provided insights into the 
biological heterogeneity of pancreatic cancer and identified genomic aberrations that 
may be of therapeutic and prognostic value [94,95,98]. These studies have identified 
somatic mutations in the proto-oncogene KRAS as a hallmark of pancreatic cancers 
in that more than 90% of pancreatic cancer cases have mutations in this gene [95,98–
100]. Several other mutations are also strongly associated with the onset of pancreatic 
cancers, including homozygous deletions in the TP53, SMAD4, and CDKN2A tumour 
suppressor genes [98,100]. Alteration in the KRAS, TP53, SMAD4 and CDKN2A are 
considered as the critical drivers of pancreatic tumorigenesis and altered signalling 
through KRAS and p53 is associated with varied treatment response to therapy and 
disease outcomes [100–102] . Nonetheless, as in other cancers, genetic alterations 
and variations in gene expression also occur in many other genes. Specifically, genes 
involved in the RB, beta-catenin, PI3K-Akt, and NOTCH pathways, commonly exhibit  
alterations that likely contributed to tumour development and progression[87,95,100]. 
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Further, while tumours displaying KRAS-pathway alterations either alone or in 
combination with TP53 pathway alterations have a poor prognosis, it has been 
shown that tumours with more complex pathway disruptions tend to have even 
poorer outcomes [101,103]. 
Notably, these studies have highlighted the alterations in key genes that function in 
these various signalling pathways. However, these studies have relied on smaller 
and/or less detailed datasets than those which are now available and have therefore 
failed to comprehensively define the specific signalling network perturbations that 
arise during different forms of pancreatic cancer. Here we explore the molecular 
characteristics of the three major pancreatic cancer subtypes and define the altered 
signalling pathways and subcellular process that, besides differentiating these 
subtypes and potentially being the underlying drivers of oncogenesis, also present a 
variety of potential prognostic biomarkers and drug targets. 
2.2 Results 
We assembled a TCGA pancreatic ductal adenocarcinoma (PDAC) dataset 
comprising clinical information for 185 patients together with their associated cellular 
transcription data (based on RNA sequencing (RNA-Seq)), protein expression data 
(based on reverse phase protein array (RPPA)), and information on genomic 
mutations and copy number alterations (CNA). We performed, survival, clustering, and 
integrative pathway and network analyses of these diverse data types, both to classify 
the pancreatic cancers into different subtypes, and to reveal their clinical 
characteristics and the potential underlying causes of oncogenesis in of these different 
subtypes.  
 
2.2.1 Pancreatic cancer subtypes display distinctive clinical outcomes 
Based on the mRNA transcription data we identified three major mRNA expression 
profiles using unsupervised hierarchical clustering (Figure 2-1A). Upon returning only 
exemplars for each profile, we identify the three PDAC subtypes as: (1) quasi-
mesenchymal PDAC (QM-PDAC; 35 samples), (2) classical PDAC (C-PDAC; 87 
samples), and exocrine-like PDAC (EL-PDAC; 48 samples), based on transcriptomic 
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classification framework established by Collision et al. [104]. These three subtypes 
were associated with distinct overall survival, and duration of disease-free survival 
(Figure 2-1B and Figure 2-1C). Specifically, both overall survival and the duration of 
disease-free survival were shorter for patients with the QM-PDAC subtype, 
intermediate for patients with the C-PDAC subtype and longer for patients with the EL-
PDAC subtype. We observed a similar trend for treatment outcomes, with patients 
having QM-PDAC and EL-PDAC respectively displaying the worst and best outcomes 
(Figure 2-1D and Figure 2-1E). Further, we did not observe significant associations 
between age, gender, or diabetes with the distribution of the PDAC subtypes (Figure 
2-1H).   Finally, we further validated the consistency of tumours within each cluster 
using a support vector machine classifier which yielded an average 10-fold cross 
validation classification accuracy of 95.5% over ten models (Figure 2-1F). We have 
summarised the distribution of tumour grades across these PDAC subtypes in Figure 
2-1G. 
2.2.2 Gene expression and pathway characteristics of different PDAC 
subtypes 
We compared gene expression profiles between all pairs of PDAC subtypes and 
identified genes that were differentially expressed within the tumours of each PDAC 
subtype (see Supplementary file 1). Using gene set enrichment analysis (GSEA), we 
established that the genes which were differentially expressed between the subtypes 
were involved in a variety of different signalling pathways [105]. Compared with 
tumours of the other subtypes, those of the QM-PDAC subtype displayed elevated 
transcription levels for genes involved in the epidermal growth factor receptor (EGFR) 
signalling pathway, the transforming growth factor–beta (TGF-β) signalling pathway, 
the phosphoinositide 3-kinase-mechanistic target of rapamycin (PI3K-mTOR) 
oncogenic pathway, the mitogen-activated protein kinase (MAPK) oncogenic pathway 
and among others (Figure 2-2). Dysregulation of the EGFR signalling pathway has 
previously been linked to tumour aggressiveness and reduced patient survival in 
various cancers including those of the breast and lung [106,107]. The PI3K-mTOR 
pathway was inactive in EL-PDAC tumours but was activated in C-PDAC and QM-
PDAC tumours.  In other cancers, including those of the breast, gastrointestinal tract 
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and prostate, activation of this pathway has been previously associated with 
significantly decreased 5-year survival rates [108].    
 
Figure 2-1: Pancreatic cancer subtypes and their clinical characteristics: (A) Clustering of mRNA 
expression data identified three major pancreatic cancer subtypes, each with distinct expression 
patterns. (B) Kaplan-Meier Curves: overall patient survival periods were lower for patients with QM-
PDAC and highest for those with EL-PDAC. Pairwise comparisons showed statistically significant 
differences between: C-PDAC vs. EL-PDAC (χ2 = 4.4, p = 0.036) and QM-PDAC vs. EL-PDAC (χ2 = 
9.7, p = 0.002). (C) Kaplan-Meier Curves: disease-free survival months were lower for patients with 
QM-PDAC and highest for those with EL-PDAC: C-PDAC vs. EL-PDAC (χ2 = 5.3, p = 0.02) and QM-










  18 
quarter of QM-PDAC patients were alive compared with nearly half of C-PDAC patients and two-thirds 
of EL-PDAC patients. Odds ratios (95% CI): C-PDAC vs QM-PDAC = 2.7(1.158 – 6.568), C-PDAC vs 
EL-PDAC = 0.541(0.261 – 1.122), EL-PDAC vs QM-PDAC = 5.51(1.95 – 13.33). (E) Treatment 
outcomes after the first course of therapy were most favourable for EL-PDAC patients and least 
favourable for QM-PDAC patients. (F) Support Vector Machine confusion matrix: a representative 
confusion matrix for the SVM classifier used to validated the purity of each molecular subtype of 
pancreatic cancer. We obtain on average a classification accuracy of 95.5% with an F1-score of 0.96. 
(G) Distribution of tumour grades across molecular subtypes: showing percentage of total count of the 
number of tumours for each grade broken down by molecular subtype. (H) Highlight tables of 
participant's age, gender, and diabetes diagnosis from left, centre and right respectively. The overall 
mean age of participants that were afflicted by C-PDAC, QM-PDAC and EL-PDAC were 65yrs., 64yrs. 
and 63yrs, respectively: one-way ANOVA test: F = 0.499, p = 0.608. No significant association was 
found between gender and diabetes diagnosis, and the presence of a particular PDAC subtypes, X2 = 
2.351, p = 0.308, and X2 = 0.611, p = 0.737, respectively. 
 
 
Figure 2-2: Enrichment Map of QM-PDAC vs C-PDAC and EL-PDAC tumours: GSEA was used to 
obtain enriched gene ontology (GO)-terms that were visualised using the Enrichment Map plug-in for 
Cytoscape. Each node represents a GO-term with similar nodes clustered together and connected by 
edges with the number of known interactors between the nodes being represented by the thickness of 
edges. The size of each node denotes the gene set size for each specific node GO-term. A map 
comparing C-PDAC and EL-PDAC tumours is shown in Fig S2. 
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Figure 2-3: Enrichment Map of Classical vs. Exocrine-like tumours: visualisation of enriched GO-terms 
obtained from GSEA results of classical vs. exocrine-like tumours. Each node represents a GO-term 
with similar nodes clustered together and connected by edges whereby the number of known interactors 
between the nodes specifies the edge thickness. The size of each node denotes the gene set size for 
each specific node GO-term. The map was created the Enrichment Map plug-in for Cytoscape.  
 
Further, we observed reduced expression of genes involved in electron transport chain 
and oxidative phosphorylation in the QM-PDAC tumours and, to a lesser degree, in 
the C-PDAC tumours (Figure 2-2 and Figure 2-4A). Since patients with QM-PDAC and 
C-PDAC tumours exhibited the worst clinical outcomes, these findings are consistent 
with the hypothesised link between the Warburg effect (characterized by decreased 
mitochondrial respiration and increased glycolytic activity) and tumour aggressiveness 
[109,110]. It is well established that  hypoxia-inducible factor 1 (HIF-1), which 
regulates glucose homeostasis by controlling the expression of multiple glycolytic 
genes and glucose transporters [111,112], drives the Warburg phenotypes of various 
cancers, including those of the lungs and clear renal cells [111,113].  
 
In support of our findings that QM-PDAC tumours have a Warburg phenotype, we 
found elevated levels of HIF1A and concomitantly lower levels of its corepressor, 
SIRT6 (Figure 2-4B) [114]. Also, we found higher transcript levels of SLC2A1 and HK2 
in C-PDAC tumours relative to EL-PDAC tumours and the highest SLC2A3 transcript 
levels in QM-PDAC tumours. The transcription of SLC2A1, SLC2A3 and HK2 is up-
regulated by HIF1A [114]. Whereas SLC2A1 and SLC2A3 respectively encode the 
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glucose transporters, GLUT1 and GLUT3, and HK2 encodes hexokinase II. 
Interestingly, among the class 1 GLUT transporters GLUT3 has the highest affinity for 
glucose and among the hexokinase isoforms, hexokinase II has the highest catalytic 
efficiency. Further, GLUT 3 and hexokinase II are both reported elevated in various 
cancers [115–117]. This is particularly significant as the combined action of GLUT3 
and hexokinase II should afford tumour cells preferential access to available glucose 
for energy production via glycolysis.  
 
We also found that the transcript levels of certain key glycolytic pathway enzymes 
varied between PDAC subtypes: these included the transcript levels of pyruvate 
kinase (PKM), lactate dehydrogenase (LDHA) and pyruvate dehydrogenase complex 
kinase-1 (PDK1) which were highest in C-PDAC tumours and lowest in EL-PDAC 
tumours (Figure 2-4B). Recently, studies have shown that the  HIF-1A induced 
expression of PDK1 limits the oxidation of pyruvate to acetyl-CoA by inhibiting the 
pyruvate dehydrogenase complex in cancers of the breast and kidney [118,119]. 
Accordingly, we suggest that in QM-PDAC and C-PDAC tumours, the upregulation of 
PDK1 and LDHA would likely favour the conversion of glucose-derived pyruvate to 
lactate, thereby promoting the Warburg effect in these PDAC subtypes (Figure 2-4C). 
 
To further investigate the degree of EGFR and TGF-β signalling pathway activation in 
the different PDAC subtypes, we mapped mRNA expression levels onto these 
pathways. We observed that there were higher mRNA levels for genes involved in 
these pathways in the QM-PDAC tumours than in the C- and EL-PDAC tumours 
(Figure 2-5 and Figure 2-6). Here and subsequently, we opted to compare QM-PDAC 
to C-PDAC and EL-PDAC tumours (referred to collectively as the “other” subtypes) 
because QM-PDAC has the most distinct molecular signature of the three PDAC 
subtypes.  
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Figure 2-4: Metabolic characteristic of PDAC subtypes:(A) PDAC subtype-specific electron transport 
chain activity: a comparison of electron transport chain activity between pancreatic cancer subtype 
based on mRNA expression data. Node denote genes-- left section = C-PDAC, middle section = QM-
PDA and right section = EL-PDAC tumours. Node are coloured based on overall subtype mRNA-
expression z-score (blue = low, grey = no change, and red = high). Edges represent various types of 
protein interaction (refer to legend to full notations for all edges). (B) PDAC subtype-specific transcript 
levels of Warburg effect associated mRNA: levels were compared between the tumour subtypes using 
one-way analysis of variance. The data are where transformed using the Box-Cox transformation. ***, 
**, and *, denote pairwise student t-test statistical significance for p values of 0.001, 0.01 and 0.05, 
respectively.  On each box, the central mark indicates the median, and the bottom and top edges of the 
box indicate the 25th and 75th percentiles, respectively. The whiskers extend to the most extreme data 
points not considered outliers, and the outliers are plotted individually using the '+' symbol. (C) Control 
of glucose metabolism by HIF1A: SLC2A1, SCL2A3, HK2, LDHA, PDK1 are positively regulated (black 
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Figure 2-5: Subtype-specific EGFR signalling pathway activity: a comparison of EGFR pathway activity 
between pancreatic cancer subtype based on mRNA expression data. Node denote genes-- left section 
= classical, middle section = QM-PDA and right section = exocrine-like tumours. Node are coloured 
based on overall subtype mRNA-expression z-score (blue = low, grey = no change, and red = high). 
EGFR Signalling Pathway
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Edges represent various types of protein interaction (refer to legend to full notations for all edges). 
 
 
Figure 2-6: Subtype-specific TGF-β signalling pathway activity: a comparison of TGF-β pathway 
activity between pancreatic cancer subtype based on mRNA expression data. Node denote genes; left 
section = classical, middle section = QM-PDA and right section = exocrine-like tumours. Node are 
coloured based on overall subtype mRNA-expression z-score (blue = low, grey = no change, and red 
= high). Edges represent various types of protein interaction (refer to legend to full notations for all 
edges). 
Many kinases have been previously implicated in carcinogenesis and, accordingly, we 
identified variations between the PDAC subtypes in the mRNA levels of the various 
kinases that are involved in the EGFR and TGF-β pathways [120]. Further, we aimed 
to pinpoint kinases that might be driving the QM-PDAC as opposed to the other 
subtypes. For this, we used an unbiased computational approach called 
TGF-beta Signalling Pathway
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Expression2Kinases to identify the kinases that might be driving the hyperactivation 
of the EGFR and TGF-β pathways in QM-PDAC tumours. Among the top ten kinases 
identified were six well-documented oncogenes (AKT1, GSKB, MTOR, MAPK1, 
MAPK14, and MAPK7), all of which are involved in the EGFR and TGF-β pathways 
(Figure 2-7A and 2C) [47]. Also present in the top ten list were CDK1, CDK2 and ATM: 
kinases which are involved in cell cycle control. Interestingly, among the top ten kinase 
that were predicted by the Expression2Kinases methods, all showed higher 
expression levels in the QM-PDAC, except AKT1 (Figure 2-7C).  
 
 
Figure 2-7: Identification of regulatory kinases: (A) Expression2Kinases solution: Heat map showing 
the top ten predicted kinases ranked according to their combined statistical score based on the number 
of substrates they phosphorylate within a protein-protein interaction subnetwork. Along the rows of the 
heatmap are proteins which are the substrates for kinases given along the columns of the heatmap. (B) 
Mapping of the top ten predicted kinases onto simplified models of the EGFR and TGF-Β signalling 
pathways. Six of the top ten ranked kinases (pink nodes) fall within these two pathways whereas the 
other predicted proteins are involved either directly in the cell cycle, or in the regulation of the cell cycle 
(blue nodes). (C) Simplified EGFR and TFG-β signalling pathway for X2K: mapping of mRNA 
expression data onto a model pathway showing the top ten X2K predicated kinase; AKT1, GSKB, 
MTOR, MAPK1, MAPK14, MAPK7, CDK1, CDK2 and ATM. Each node denotes a pathway protein, the 
left section denotes QM-PDA z-scored mRNA expression, and the right section denotes Other subtypes 
z-scored mRNA expression. Green = low expression, grey = no change, and red = high expression.  
 
2.2.3 The gene alterations landscape of PDAC subtypes 
We evaluated the scope of genomic alterations in PDAC subtypes by focusing on the 
types of genetic changes that are known to promote oncogenesis. Specifically, these 
encompassed gain-of-function mutations in oncogenes (OGs), amplification of OGs, 
A B C
  25 
loss-of-function mutations in tumour suppressor genes (TSGs), and deletions in TSGs. 
Across all the PDAC subtypes we found that, as has been reported elsewhere, KRAS, 
TP53, CDKN2A, SMAD4, and CDKN2B were the most commonly altered genes 
(Figure 2-8A) [87,94,95].  
 
SMAD4 signals through the canonical TGF-β pathway and  therefore deletions in 
SMAD4 should limit signalling through this pathway [121]: a factor that may seem 
inconsistent with our earlier finding that genes in this pathway display elevated levels 
of transcription (Figure 2-6 and Figure 2-7C). However, SMAD4 loss does not initiate 
tumorigenesis in human pancreatic cancers  [121–123]. Further, in pancreatic tumours 
displaying either SMAD4 deletions or SMAD4 under-expression, ligand stimulation of 
the TGF-β pathways activates non-canonical pathways including the MAPK, p38/JNK, 
and PI3K-mTOR pathways which can function independently of SMAD signalling 
[121,124,125]. Moreover, we found that among the PDAC subtypes, QM-PDAC had 
the lowest transcript levels of genes in the SMAD gene family (SMAD2/3/4/7; Figure 
2-8a). Therefore, consistent with other studies, these results indicated an association 
between reduced SMAD expression and poor survival [124,126].  
 
Whereas we observed higher gene deletion frequencies in EL-PDAC tumours than in 
QM-PDAC and C-PDAC tumours, QM-PDAC and C-PDAC tumours displayed higher 
gene amplification frequencies (Figure 2-8C). We observed 118 that were common 
across all the PDAC subtypes (Figure 2-8B), mostly impacting genes involved in 
diverse cell signalling pathways (Figure 2-8B and 2-8D); a finding consistent with the 
hypothesis that, like most other cancers, PDAC is primarily a consequence of 
disrupted signal transduction pathways (Figure 2-8D and 2-8E) [99,127].  
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Figure 2-8: Mutation and gene copy number analyses: (A) Genes with the most alterations in PDAC 
tumours. The only genetic alterations considered are mutations in, and amplifications of known 
oncogenes, and mutations in, and deletions of, known tumour suppressor genes. (B) The distribution 
of alterations among the three PDAC subtypes. Refer to supplementary file 5 for details concerning 
alterations in each set. (C) The extent of genomic alterations expressed as a percentage of total 
numbers of alterations found within the tumours of each PDAC subtype. Each cell in the bar-grid 
represents a mutant gene. (D) Reactome pathway enrichment results of the 118 genes that are 
commonly altered in tumour cells of all three PDAC subtypes. Refer to supplementary file 6 for the 
complete list of Reactome pathways that represent significantly enriched genetic alterations in the 
different PDAC subtypes. (E) The predicted extent of mutation-induced pathway dysregulation for the 
different PDAC subtypes. (F) The distribution of mutation-induced pathway dysregulations for mutations 
specifically associated with particular PDAC subtypes and common pathway enrichment. The non-
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We uncovered little overlap in the signalling pathways that were impacted by genetic 
alterations that were observed in only one of the PDAC subtypes (Figure 2-8F and 
Figure 2-9A; 2-9B; 2-9C). Further, we found that 62% of the pathways affected by 
mutations were altered in tumours belonging to at least two PDAC subtypes, whereas 
only 18%, 11%, and 8% of altered pathways were unique to C-PDAC, QM-PDAC, and 
E-PDAC tumours, respectively. This suggests that only a small proportion of mutations 
contribute to differences in the signalling pathway perturbations that are seen between 
the subtypes.  Conversely, we therefore also suggest that most of the oncogenesis 




Figure 2-9: Enriched Reactome pathways: Showing the top ranked dysregulated Reactome pathways 
based on mutations that are specific to each pancreatic cancer subtype. The size of each bar represents 
the combined score for each pathway (also see supplementary file 5). (A) Top 13 pathways over 
presented by mutations unique to C-PDAC tumours. (B) Top 13 pathways over presented by mutations 
unique to QM-PDAC. (C) Top 13 pathways over presented by mutations unique to EL-PDAC tumours. 
 
2.2.4 Integrative pathway analysis 
We used the co-occurring mutated driver pathway (CoMDP) mathematical algorithm 
to discover de novo, two co-occurring pathways that may be driving the progression 
of PDAC; the first pathway involved the genes KRAS, COL4L4 and FBWX7, and the 
second involved the genes SMAD4, TP53, PHF24, PRG4, PI3KCA, RPTOR and 
EP300 (Figure 2-10A) [128]. We expanded the CoMDP solution pathways using 
known protein-protein interactions to generate a network enriched with MAPK, PI3K, 
and TP53 pathway members. Here, we found that two of the genes in the CoMDP 
solution pathways, PRG4 and PHF24, did not map to any signal transduction pathway, 
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need de be defined. In particular, virtually nothing is known about PHF24 [129].  
To further investigate the degrees of alteration that are evident in the expanded 
CoMDP solution networks for the different PDAC subtypes, we mapped a combined 
dataset of mRNA transcript levels, protein expression levels, mutations and CNA onto 
these networks. We found that alterations in p53 and cell cycle checkpoint pathway 
genes were most apparent in C-PDAC tumours (Figure 2-10B and 2-10C), whereas 
alterations in specific MAPK and PI3K-mTOR pathway genes were more apparent in 
QM-PDAC tumours (Figure 2-10D and 2-10E). We found that the PI3K-mTOR and 
MAPK pathways were altered in 93% of all PDAC tumours. Alterations, included the 
activation of, among others, the PI3KCA (in 13% of tumours), AKT (in 27%) and BRAF 
(in 9%) genes, and the inactivation of the PTEN (in 4% of tumours), TSC1/2 (in 7%) 
and FOXO3 (in 5%) genes. Alterations in the PI3KCA oncogene and its negative 
regulator, PTEN, occur in cancers of the colon, breast, and prostate: cancers where 
the co-occurrence of PI3KCA and PTEN mutations appears to both drive oncogenesis, 
and reduce anticancer drug sensitivity [98,130]. Furthermore, we observed that 
PIK3R1 (the regulatory subunit of PI3K) was inactivated in 6% of PDAC tumours; 
inactivated PIK3R1 promotes the phosphorylation of AKT, which itself promotes 
oncogenesis as it activates numerous OGs and inhibits TSGs within the cell [131,132].  
Alterations in the p53 and cell cycle pathways are frequent in cancer, and here we 
found that such changes were apparent in 85% of the tumours examined [133]. In 
addition to activated MDM2 and MDM4 (which both inhibit p53 activity), MYC, and 
CDK2/4/6, we found that p53 was inactivated in 58% of all tumours.  Similarly, 
CDKN2A, CDKN2B and ATM (a kinase that activates p53) were inactivated in 35%, 
42% and 3% of all tumours, respectively [133,134]. This suggests that, within the p53 
and cell cycle checkpoint pathways, hyperactivated OGs such as MYC, MDM2, CDKs 
and inactivated TSGs such as TP53, CDKN2A and CDKN2B, may act together to 
promote oncogenesis both by limiting the repair of damaged DNA, and by permitting 
affected cells to proliferate uncontrollably through the inhibition of apoptosis [133,134]. 
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Figure 2-10: Integrative pathway analysis: (A) The two co-occurring pathways in PDAC that are 
predicted to drive oncogenesis based on the mutational landscape representing two common driver 
pathways. (B) Alterations in p53 and cell cycle checkpoint pathways. p-value = C-PDAC vs Other 
subtypes, calculated using Fisher's exact test. Red indicates activating genetic alterations whereas blue 
indicates inactivating alterations. Darker shades correspond to higher alteration frequencies. Each node 
within the pathway represent a gene and the highlighted segments within each node and the percentage 
representing the alteration in the three PDAC subtype: C-PDAC, QM-PDAC and EL-PDAC from left, 
centre, and right, respectively. (C) The pattern of genetic alteration in selected genes that encode 
proteins involved in the p53 and cell cycle checkpoint pathways. (D) Alterations in the MAPK, RTKs 
and PI3K signalling pathways. p-values = QM-PDAC vs Other subtypes, calculated using Fisher's exact 





p53 pathways & cell cycle checkpoint: altered in 85% of Tumours
Partial alteration fingerprint: p53 pathway & cell cycle checkpoint
PI3K-AKT & MAPK pathways: altered in 93% tumours
Partial alterations fingerprint: PI3K-AKT & MAPK pathways
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the literature. (e) The pattern of genetic alterations in selected genes that encode components of the 
MAPK and PI3K-mTOR pathways. 
 
Consistent with previous observations, we found mutations, CNAs and changes in 
mRNA transcription and protein expression levels for proteins that participate in 
various signalling pathways that have previously been associated with pancreatic 
cancer [87,95,98]. Specifically, we observed alterations in the Notch (61%), apoptosis 
(32%) and NF-kβ (19%) pathways (Figure 2-11). Also, we found a variety of alterations 
in 41 genes that encode the ATP-binding cassette (ABC) transporter proteins in 72%, 
82% and 79% of all tumours that belong to the C-PDAC, QM-PDAC and EL-PDAC 
subtypes, respectively (Figure 2-11D). The most altered ABC transporter gene in any 
PDAC subtype was ABCC9; found altered in 21% of all in QM-PDAC tumours. Overall, 
we observed that 78% of all PDAC tumours harboured a genetic alteration in at least 
one ABC transporter gene. ABC transporter-mediated energy-dependent efflux of a 
multitude of unrelated classes of anticancer drugs across membranes is a major cause 
of multidrug resistance and chemotherapeutic failures during cancer therapy 
[135,136]. Therefore, future efforts to determine tumour cell ABC transporter gene 
mutations that accentuate the activities of their encoded transporters are expected to 
guide precision medicine [137]. 
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Figure 2-11: Genetic alterations in three critical signalling pathways: Integrated alterations of mutations, 
copy number alteration, mRNA expression and protein levels are shown for (A) Notch signalling 
pathway (B) apoptosis pathway, and (C) NF-kβ pathway. Red indicates activating genetic alterations 
whereas blue indicates inactivating alterations. Darker shades correspond to higher alteration 
frequencies. Each node within the pathway represent a gene and the highlighted segments within each 
node and the percentage representing the alteration in the three PDAC subtype: C-PDAC, QM-PDAC 
and EL-PDAC from left, centre, and right, respectively. (D) The heatmap of integrated alterations in 
a
b c
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ATP-binding cassette encoding genes. The intensity denotes the frequency of alterations, with darker 
shades of blue representing a higher proportion of alterations.   
 
2.2.5 Connectivity of genomic alterations to transcription factors and their 
pathway activities in pancreatic cancer 
To link genomic changes to transcriptional events, we applied the Tied Diffusion 
Through Interacting Event (TieDIE) approach to reveal a protein interaction 
subnetwork that connects altered genes to transcription factors and their putative 
targets [138]; a network referred to below as the TieDIE subnetwork. Additionally, we 
used the PARADIGM-shift algorithm to infer pathway activity levels of all proteins that 
are known to participate in various signalling pathways in each of the three PDAC 
subtypes [139]. Furthermore, using heat diffusion analysis from the MAPK1 and TP53 
nodes of the TieDIE subnetwork, we extracted two pathways that recapitulated 
signalling via the MAPK and p53 pathways.  
The MAPK1 network was enriched with proteins whose associated mRNA 
transcription levels were significantly higher in QM-PDAC tumours compared to other 
PDAC subtypes.  These proteins included EGFR (a receptor of the EGFR pathway 
that we found activated in QM-PDAC tumours), SOS1 and GRB2 (both of which are 
upstream signalling proteins in the canonical MAPK signalling pathway; Figure 2-
12A) [140]. Also, the MAPK network connected TFs that are induced upon activation 
of the MAPK pathway, to proteins which are known to promote oncogenesis (such as 
FOS, JUN, ATF2 and ESR1). This inferred connectivity was further supported by the 
PARADIGM analysis which predicted that ESR1, JUN, GRB2 and CBL would have 
high degrees of activity [140,141].  




  34 
Figure 2-12: TieDIE subnetworks: (A) MAPK heat diffusion sub-network: pathway extracted from the 
TieDIE subnetwork using heat diffusion analysis from the MAPK1 network node. (B) p53 heat diffusion 
sub-network: pathway extracted from the TieDIE solution network using heat diffusion analysis from the 
TP53 network node. Each node indicates a pathway protein shown as concentric rings. The inner node 
denotes differential mRNA expression (Benjamini-Hochberg adjusted p < 0.05) bias for genes when 
comparing the QM-PDAC subtype tumours to those of the other PDAC subtypes (red = QM-PDAC bias, 
blue = bias towards other subtypes). The second ring indicates the presence of genomic alterations for 
that gene in each patient’s tumour, with each patient’s tumour being denoted by a spoke within the ring. 
The third ring shows mRNA expression levels for each tumour sample (red = high, blue = low). The 
outer ring indicates the PARADIGM inferred pathway activity for that protein in each tumour sample 
(red = high, blue = low). Arrows indicate known protein-protein interactions extracted from UCSC Super 
pathway, KEA, ChEA or inferred from the literature. We have attempted to make the visualisation 
clearer by omitting some interactions between some network nodes. 
The p53 network, on the other hand, was more prominent in C-PDAC and EL-PDAC 
tumours, and it connected signalling proteins to various TFs that are known to promote 
carcinogenesis, including ATF3, PRKCD, NFKB1 and NFKBIA [142–144]. These TFs 
were also predicted by PARADIGM to have a high degree of activity (Figure 2-12B).  
Collectively these analyses emphasise that certain pathways may be more prominent 
than others in the different PDAC subtypes. Differences between the PDAC subtypes 
in the activity of specific signal transduction proteins suggests that some of these 
proteins could be targets of PDAC subtype-specific anti-cancer drugs (Figure 2-13 and 
Table 2-1).  
  35 
 
Figure 2-13: MAPK heat diffusion sub-network: pathway extracted from the TieDIE solution network by 
heat diffusion for the MAPK1 network node and annotated with FDA approved anticancer drugs that 
are known to target specific pathway proteins. Each node indicates a pathway protein shown as 
concentric rings. The size of the node is proportional to the number of FDA approved drug for that 
particular pathway protein. The inner node detonates mRNA differential expression (Benjamini-
Hochberg adjusted p < 0.05) biased for the statistically significant expressed gene between QM-PDA 
and other subtypes (red = QM-PDA bias, blue = bias towards other subtypes). The second ring shows 
the presence of genomic alterations for that gene in each sample that is denoted by a spoke within the 
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ring. The third ring shows mRNA expression levels per samples (red = high, blue = low). The outer ring 
shows PARADIGM inferred activity for that gene in each sample (red = high, blue = low). Arrows indicate 
known protein-protein interaction extracted from UCSC Super pathway, KEA, ChEA or curated from 
the literature. We have made the visualisation easy by omitting some interactions between network 
nodes.   
Table 2-1: Some dysregulated pathway drug targets in clinical trial 
Drug Target Phases Status NCT Number 
Palbociclib, Gedatolisib CDK4/CDK6 Phase 1 Recruiting NCT03065062 
MK0752, gemcitabine, + NOTCH Phase 1 Completed NCT01098344 
NIS793, PDR001 TGF Phase 1 Recruiting NCT02947165 
Nimotuzumab, Gemcitabine EGFR Phase 3 Recruiting NCT02395016 
MK-0646, Gemcitabine, Erlotinib mTOR Phase 1/2 Active, not recruiting NCT00769483 
Ixabepilone, Cetuximab EGFR Phase 2 Completed NCT00383149 
Irinotecan, Hydrochloride, Veliparib ESR1 Phase 1 Recruiting NCT00576654 
Gemcitabine, Capecitabine, Erlotinib EGFR/mTOR/PI3K Phase 1 Completed NCT00480584 
Galunisertib, Durvalumab TGF Phase 1 Recruiting NCT02734160 
Everolimus, Octreotide, Acetate mTOR Phase 1 Completed NCT01204476 
Erlotinib, Gemcitabine, Oxaliplatin EGFR Phase 2 Completed NCT01505413 
Docetaxel, Irinotecan Hydrochloride KRAS Phase 2 Completed NCT00042939 
Cetuximab, Erlotinib, Hydrochloride EGFR Phase 1 Completed NCT00397384 
Cediranib, Maleate, Olaparib ESR1 Phase 2 Recruiting NCT02498613 
Capecitabine, Cetuximab, Everolimus mTOR/KRAS/EGFR Phase 1/2 Completed NCT01077986 
Afatinib, Selumetinib, Docetaxel PI3K Phase 1/2 Recruiting NCT02450656 
Afatinib, Binimetinib, Capivasertib, + CDK4/CDK6 Phase 2 Recruiting NCT02465060 
Targeted-therapy drug that are currently being evaluated in clinical trial for treatment of pancreatic cancer. + 
denotes more drug being used in combination. NCT denotes the national clinical trial. Information concerning 
clinical trials was obtained from www.clinicaltrials.gov.   
2.3 Discussion 
Through comprehensive transcriptomic and integrative profiling of pancreatic cancer, 
we have uncovered various functional alterations and signalling pathway perturbations 
and revealed how these alterations and perturbations might be associated with 
clinically relevant differences between patients with different PDAC subtypes. In 
particular, the discovery that QM-PDAC tumours are characterised by what is likely to 
be ESR1 and NTRK1 transcription factor-mediated over-activation of genes 
associated with the EGFR and TGF-β pathways, provides a rationale to target these 
tumours with drugs that either downregulate ESR1 and NTRK1, or inhibit EGFR and 
TGFBR2 (Figure 2-13) [145,146].  
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Furthermore, we find that, in general, PDAC is characterised by pervasive RTK, MAPK 
and PI3K-mTOR alterations [94,95,147] and that over 90% of the potentially 
oncogenic alterations occur in genes that are directly involved in the RTK, MAPK and 
PI3K-mTOR signalling pathways. It is well established that PDAC tumours frequently 
respond to MAPK and/or PI3K-mTOR pathway inhibitors [148,149]. While cases 
where these inhibitors have failed to provide therapeutic benefits have highlighted the 
heterogeneity of PDAC, they have also emphasised the importance of finding 
additional drugs that are either more generally applicable to PDAC treatment, or which 
can be used to target the signalling pathways that are most relevant for specific PDAC 
subtypes [149–151]. We identified that the most prominent cell signalling changes in 
EL-PDAC and C-PDAC tumours were within the p53 and cell cycle checkpoint 
pathways; hinting that these tumours might respond to cell cycle inhibitors. Consistent 
with our findings, other PDAC studies have also reported co-occurring mutations in 
genes involved in the p53 and cell cycle pathways. Collectively these studies provide 
a rationale for potentially treating PDAC using an approach that synchronously targets 
all of these pathways [152–154]. Furthermore, we have uncovered other receptors, 
intermediary signal transduction proteins and TF targets that may drive oncogenesis: 
all of which could be targeted by drugs designed to specifically treat QM- C- or EL-
PDAC tumours.  
 
Alterations in metabolism and cellular bioenergetics are hallmarks of cancer cells and 
represent an active area of research that is anticipated to yield novel anti-cancer drugs 
that could be used in combination with targeted-therapies or chemotherapy [155–157]. 
Here, we found that QM-PDAC and, albeit to a lesser extent, C-PDAC tumours exhibit 
a Warburg metabolic phenotype (Figure 2-4) [153]. Associations between the Warburg 
phenotype and both increased disease aggressiveness and poorer clinical outcomes 
have been previously reported [153,156]. As expected, we observed decreased 
overall survival and a shorter duration of disease-free survival in patients with QM- 
and C-PDAC tumours (i.e. tumours with the Warburg phenotype) relative to patients 
with EL-PDAC tumours (i.e. those without the Warburg phenotype). In this regard, 
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scrutinising the metabolic differences between PDAC tumour subtypes is likely to yield 
further leads for the development of novel therapeutic approaches. 
 
We observed that most of the genomic alterations which are found within PDAC 
tumour cells are found in tumours belonging to all three of the defined PDAC subtypes. 
This finding suggests that improved responses to targeted-therapies may be 
achievable by systematic targeting of hub kinases within the multiple alternative 
signalling pathways that enable cancer cells to frequently acquire resistance 
[158,159].  
 
By integrative analyses of genomic, transcriptomic, and proteomic data, we have 
uncovered novel signalling pathway aberrations that exist in PDAC tumour cells at the 
DNA, mRNA and protein levels. Altogether, our analyses have revealed widespread 
signalling network perturbations in PDAC subtypes, many of which could likely impact 
treatment outcomes and which are therefore also potential targets for novel anticancer 
drugs.   
2.4 Methods  
We obtained data for 185 PDAC patients involved in the TCGA project. Besides 
treatment outcomes these data include: whole exome sequence (WES; n = 185), 
transcriptome data (determined using RNAseq; n = 179); DNA copy number and 
mutation data (n = 179), and targeted proteome data (determined using RPPA; n = 
123). Not all types of data were available for all patients because of assay failures, 
incomplete specimen availability and quality of issues with certain samples. All data 
used in our analyses are available from the TCGA website; 
https://portal.gdc.cancer.gov/repository.  
 
2.4.1 Transcriptome-based classification 
We performed unsupervised hierarchical clustering on RNA-seq data to identify three 
distinct PDAC subtypes. Before clustering, we removed data for unexpressed genes 
and genes that exhibited little variation between patients. Then, using the 
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transcriptomic classification framework established by Collision et al. [97], we 
classified the pancreatic cancer clusters as C-PDAC, QM-PDAC and EL-PDAC; 
respectively corresponding to clusters 1, 2 and 3 [97]. To return only exemplars for 
each cluster, we applied an anomaly detection algorithm based on an approximate 
Gaussian distribution [160]. Finally, we further validated the consistency of tumours 
within each cluster using a support vector machine classifier which yielded an average 
10-fold cross validation classification accuracy of 95.5% over ten models (Figure 2-
1F). We have summarised the distribution of tumour grades across these PDAC 
subtypes in Figure 2-1G. 
2.4.2 Treatment outcomes 
We integrated mRNA expression-based classification of PDAC subtypes with clinical 
information to review tumour characteristics specific to each of the PDAC 
subtypes. The Kaplan-Meier method was used to estimate overall survival and the 
duration of disease-free survival in a pairwise manner between subtypes [160]. 
Furthermore, the Fisher exact test was used evaluate associations between tumour 
subtypes and various clinical variables including treatment outcomes at the first, and 
later courses of treatment. 
 
2.4.3 Differential gene expression, functional and pathways analyses 
The identification of differentially expressed genes was performed in MATLAB using 
an implementation based on the negative binomial model (see supplementary file 1)  
[161,162]. Gene set enrichment analysis (GSEA) was employed to extract knowledge 
of overrepresented Gene Ontology (GO) terms for various functional processes and 
signalling pathways between molecular subtypes [105,163]. Complete GSEA results 
are provided in supplementary files 2A, 2B and 2C, for C-PDAC vs QM-PDAC, C-
PDAC vs EL-PDAC and QM-PDAC vs EL-PDAC, respectively. Visualisation of 
significantly enriched GO terms of functional process and signalling pathways 
between subtypes was done in the Cytoscape plugin, Enrichment Map [164,165]. 
Furthermore, the mapping of gene expression levels onto template WikiPathways of 
the EGFR and TGF-β signalling pathways and the electron transport chain was done 
using the software PathVisio 3 (See Figure 2-5, 2-6, 2-7A, and 2-7B) [166,167]. For 
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this, we used z-score normalised expression data categorised into three levels: 1) Low 
for z-scores below -0.5; 2) no change for z-scores between -0.5 to 0.5; and 3) high for 
z-score above 0.5. The highlighted scale was chosen to consistently capture variations 
in gene expression across the entire pathways. 
 
2.4.4 Prediction of regulator kinases 
We computationally predicted upstream regulatory kinases that likely effect the 
observed differences in the gene expression signatures between QM-PDAC and the 
other PDAC subtypes using Expression2Kinases (X2K) [168]. X2K employs a reverse 
engineering network-based approach to predict upstream regulatory kinases based 
on prior knowledge. We obtained a list of differentially expressed genes between QM-
PDAC and the others PDAC subtypes: 242 up-regulated genes and 1011 down-
regulated genes based empirical Bayes statistics. Using this gene list, we predicted 
upstream regulatory TFs that are likely to be responsible for the observed changes in 
gene expression using the Chromatin Immunoprecipitation (ChIP) Enrichment 
Analysis (ChEA; 2016) [169]. In the next analysis, we linked the top 10 predicted TFs 
to upstream regulatory mechanisms by generating a TF-intermediate protein-protein 
interaction sub-network based on prior knowledge (Figure 2-14). Intermediate protein-
protein interaction sub-network had 180 nodes with 1816 edges and is enriched in co-
regulators, kinases and TFs that are experimentally verified to physically interact.  
Finally, we analysed the sub-network for enriched targets of known protein kinases 
that are likely to phosphorylate proteins within the sub-network using the Kinase 
Enrichment Analysis (KEA; 2015) [170]. See supplementary file 3 for a full list of 
computationally predicted kinases and their rankings. 
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Figure 2-14: Expression2Kinases pipeline. The computationally predicted kinases are extracted from 
the protein-protein subnetwork and ranked according to the number of targets that each kinase 
phosphorylated with in the subnetwork.  
2.4.5 Mutation and copy number alteration analyses  
We evaluated the scope of genomic alterations in PDAC subtypes using significantly 
mutated genes, and copy number alteration identifications obtained from MutSigCV 
and GISTIC2.0 outputs, respectively [171,172]. Data for the genomic alteration 
analysis was processed as follows: oncogenes (OGs) and tumour suppressor genes 
(TSGs) in the samples were annotated using information from multiple sources. These 
include the Sanger Consensus Cancer Gene Database (699 OGs and TSGs), the 
UniProt Knowledgebase (304 OGs and 741 TSGs), the TSGene database (1,219 
TSGs) and the ONGene database (725 OGs) [36,47,173,174]. Collation of data from 
these sources yielded a list of 3,688 OGs and TSGs, representing 2,773 unique genes 
(969 OGs and 1,804 TSGs).  We utilised this list of OGs and TSGs to extract genetic 
changes anticipated to have a potential impact on the oncogenesis of pancreatic 
cancer. Explicitly, we returned only gain-of-function mutations and gene amplifications 
for known OGs. Also, for known TSGs, we returned loss-of-function genetic changes 
that involve mutations and deletions. Using these processed data, we identified 
frequently altered genes that likely have detrimental impacts concerning pancreatic 
carcinogenesis. We compared gene mutations between the PDAC subtypes to 
generate lists of mutations that are common among subtypes or unique to particular 
subtypes (see supplementary file 4). Using these lists, we performed a Reactome 
pathway enrichment analysis by querying Enrichr either with genes that were 
consistently altered in tumours of all three PDAC subtypes, or with genes that were 
altered in only one of the PDAC subtypes (see supplement file 5) [175].  
2.4.6 Integrative analysis of expression and genomic alterations 
2.4.6.1 Identification of co-occurring driver pathways 
To discover driver pathways based on the patterns of mutations associated with 
PDAC, we applied the CoMDP algorithm which employs a mathematical programming 
method to identify de novo driver pathways in cancer from mutation profiles [128]. 
Briefly, this method identifies pathways that have a set of mutated genes with both 
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high coverage (i.e. present in the tumours of multiple individuals) and high exclusivity, 
and the pathways exhibit a statistically significant co-occurrence pattern. Using 
mutation data, we ran the CoMDP test with K = 5 to 11 (K equals the total gene set 
size) to return mutated driver pathways for all K values (Table 2-1). Genes in the 
CoMDP solution for K = 10 were connected using experimentally verified protein-
protein interactions to generate an intermediary network. The solution network was 
enriched with members of the PI3K, MAPK, p53 and cell cycle regulation pathways. 
To visualise the extent of pathway aberration at DNA, mRNA and protein levels, we 
mapped genomic alteration data, mRNA transcript abundance data and protein 
expression data onto the network. For the genomic alteration data, we only considered 
gain-of-function mutations and gene amplifications for the OGs, and loss-of-function 
mutations and deletions for the TSGs. For the transcription and protein expression 
data we only considered OGs that had a degree of upregulation indicated by a > 2 Z-
score and for the TSGs a degree of downregulation indicated by a < -2 X-score.  The 
generated combined dataset was mapped on signalling pathways over-represented in 
the CoMDP solution network expanded using a prior-knowledge network. Additionally, 
plots of alteration patterns in genes among tumours were generated using the R 
package complex heatmaps [128]. Mapping of alterations onto genes in pathways 
shown in figure S8a, S8b and S8c were done using the software PathwayMapper 
[176].   
 
Table 2-2: Co-occurring gene sets in pancreatic cancer 
K Gene set 1 Gene set 2 n1 n2 r1,2 Co-occurrence 
5 KRAS SMAD4 TP53 PHF24 
CDKN2A 
130 134 0.84 < 0.001 
6 KRAS CDKN2B SMAD4 TP53 PHF24 
CDKN2A 
136 134 0.89 < 0.001 
7 KRAS CDKN2B 
COL4A4 
SMAD4 TP53 PHF24 
CDKN2A 
138 134 0.9 < 0.001 
8 KRAS COL4A4 
FBXW7 
SMAD4 TP53 PHF24 
RPTOR EP300 
135 128 0.88 < 0.001 
9 KRAS COL4A4 
FBXW7 
SMAD4 TP53 PHF24 
RPTOR EP300 PRG4 
135 130 0.89 < 0.001 
10 KRAS COL4A4 
FBXW7 
SMAD4 TP53 PHF24 
RPTOR EP300 PRG4 
PIK3CA 
135 132 0.91 < 0.001 
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11 KRAS COL4A4 
FBXW7 SALL2 
SMAD4 TP53 PHF24 
RPTOR EP300 PRG4 
PRDM11 
137 132 0.91 < 0.001 
In the Table, K is the combined gene set size (gene set 1 and gene set 2). Gene sets 1 and 2, represent 
co-occurring driver pathway in pancreatic cancer. n1 and n2 denote the coverage of genomic alterations 
in pancreatic cancer and r1,2 is the ratio of the common coverage to their union coverage (i.e., co-
occurrence ratio). Co-occurrence P represents the p-value of the co-occurrence significance of both 
pathways 
2.4.6.2 Inferring gene activity from pathway analysis of copy number and expression data  
We used PARADIGM-shift, a probabilistic graphical model approach that infers the 
activity of signalling pathway proteins by detecting differences in the expected activity 
of a protein on its downstream target relative to what is expected given it upstream 
modulator [128]. We ran PARADIGM with default settings using three datasets as 
inputs: (i) a dataset including only statistically significant CNA as determined by 
GISTIC2, (ii) a normalised gene expression dataset matching the CNA input file, and 
(iii) a custom UCSC Pathway formatted file. Pathway information of known gene 
interactions was created from various sources including Reactome pathways, KEGG 
Pathways, the KEA database, the ChEA database and the UCSC Super pathway 
[10,139,170]. PARADIGM predicted integrated pathway levels results are provided in 
supplementary file 6. 
 
2.4.6.3 Identification of genomic perturbation associated with transcriptional changes 
Genomic perturbations in PDAC subtypes were connected to associated 
transcriptional changes using TieDIE [138]. This method uses a heat diffusion process 
to identify relevant pathways that might be altered in tumours. To reveal sub-networks 
that distinguish QM-PDAC from the other PDAC subtypes, using genes that we found 
altered in at least 5% of all tumours, we generated a ranked list of genes that were 
differentially mutated between QM-PDAC tumours and those of the other PDAC 
subtypes using the Fisher's exact test (Figure 2-15A). The resulting genes are 
assumed to be responsible for the distinctive molecular signatures between 
subtypes—these were used as upstream inputs in TieDIE. A downstream input file 
was generated by computationally identifying the TFs that are most likely to be 
responsible for the difference in the transcriptome signatures between the QM-PDAC 
tumours and those of the other PDAC subtypes. The upstream and downstream input 
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files, together with a custom super pathway, were used in TieDIE to compute a sub-
network connecting genomic alterations to transcriptional events (Figure 2-15B). The 
resulting sub-network had 158 nodes with 1127 edges and is enriched in mutated 
proteins and their TF targets likely response for the molecular differences between 
QM-PDA and other pancreatic cancer subtypes. We performed a secondary heat 
diffusion query on the TieDIE solution sub-network from the MAPK1 and TP53 nodes.  
Both MAPK1 And TP53 were flagged as being of likely importance based on both the 
numerous alterations of these genes within PDAC tumours and the pathway analysis 
that we had previously performed. These analyses produced two subnetworks that 
recapitulate signalling through the MAPK1 and TP53 pathways to their downstream 
TFs. 
 
Figure 2-15: Genomic alteration bias and TieDIE subnetwork: (A) Genomic alterations in QM-PDA vs. 
Other Subtypes. Each node represents a gene, who’s colour shows details about the bias alterations 
and the node size is proportional to the overall alteration frequency in in pancreatic cancer. TP53 and 
KRAS are excluded from the plot and they don’t show any bias. (B) TieDIE solution network: 
Visualisation of the TieDIE solution gene connectivity subnetwork. The nodes in highlighted in yellow 
represent the TP53 heat-diffusion network extracted the TieDIE solution network. 
2.4.7 Statistical analyses  
Except were stated otherwise all statistical analyses were performed in MATLAB 
2017b. The Fisher's exact test was used assess associations between categorical 
variables.  The Wilcoxon rank sum test and Kruskal-Wallis test or independent sample 
Student t-test and one-way analysis of variance were used for continuous variables 
A B
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were appropriate. Statistical tests were considered significant at p < 0.05 for single 
comparisons, and Benjamini-Hochberg adjusted p-values for multiple comparisons.  
2.6 Supplementary Information 
Supplemental Information can be found with this article online at 
https://doi.org/10.18632/oncotarget.25632 
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Chapter 3 : Machine Learning and Network Analyses Reveals Disease 
Subtypes of Pancreatic Cancer and their Molecular Characteristics 
This section is a reformatting of a paper published in Scientific Reports [177]: 
https://www.nature.com/articles/s41598-020-58290-2 
Musalula Sinkala, Nicola Mulder, Darren Martin 
3.1 Introduction 
Pancreatic cancer is a heterogeneous disease that is characterised by poor clinical 
outcomes and few effective treatment options. Attempts to define a standard 
classification for tumours of the pancreas have been ongoing for decades [178–180]. 
In general, the approaches that are currently used for making both outcome 
predictions and treatment decisions are based on histological subtyping and clinical 
parameters such as the disease stage, metastasis, and the resectability of tumours 
[181,182].  Recently, however, the advent of molecular profiling has laid the foundation 
for quantitatively profiling tumours based on their genome-wide gene transcription 
profiles, protein expression profiles and/or mutational landscapes [183–186]. These 
profiling methods promise a more accurate and precise definition of tumour subtypes 
and better predictions of how particular tumour types will respond to different 
treatments.  
 
Further, molecular data that is used to construct the molecular profiles of particular 
cancers have been used to identify the perturbances in the cellular regulatory networks 
that characterize these cancers: often revealing numerous potential drug targets within 
various signalling pathways. These molecular data together with the known molecular 
profiles of numerous well characterized cancer cell lines can even be leveraged using 
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machine learning methods to predict the responses of particular patient tumour 
subtypes to different anticancer drugs [7,187].  
A crucial resource for the discovery of useful diagnostic biomarkers and potential 
anticancer drug targets are large-scale datasets comprising, among other data types, 
extensive genomic, transcriptomic and proteomic profiles of matched healthy and 
tumorous tissues. These datasets, some of which are compiled and maintained by 
The Cancer Genome Atlas (TCGA) and the International Cancer Genome Consortium 
(ICGC) are helping us uncover the molecular characteristics and signalling pathway 
perturbations that define specific cancer subtypes [9,96]. 
Among the cancers that are well represented in these data collections is pancreatic 
cancer. Molecular profiling analyses of the pancreatic tumour datasets have identified 
both distinct pancreatic cancer subtypes, and mutations of the genes, KRAS, TP53, 
SMAD4 and CDKN2A as potential drivers of pancreatic cancer [86,188–191].  
Although the biomarkers that differentiate between different pancreatic cancer 
subtypes could eventually inform treatment decisions, there are as yet no available 
subtype-specific treatment options for this type of cancer. There is, therefore, a 
pressing need to, firstly, find a set of biomarkers that can be used to accurately and 
sensitively identify the molecular subtypes of pancreatic cancer and, secondly, to 
identify suitable targets for drug development among these biomarkers.  
Definitions of disease subtypes is a perpetual process, with classifiers and cut-offs 
that differentiate between the subtypes, essentially needing to be continually re-
defined and refined as more molecular data and better molecular profiling tools 
become available. As classification schemes for pancreatic cancers improve, it is 
expected that additional specific molecular correlates of patient survival, responses to 
anticancer drugs, and tumour aggressiveness will be uncovered. Armed with such 
knowledge, we could develop better prognostic and diagnostic methods, and select 
the best drugs to treat specific pancreatic cancer subtypes. Further, more subtype-
specific molecular features could potentially enhance the accuracy with which 
machine learning methods could predict the drug response profiles of specific 
pancreatic tumours, thus leading to improved disease outcomes.   
  48 
However, it remains technically difficult to effectively leverage the diverse and ever-
increasing data relating to pancreatic tumours [192–194]. These difficulties include, 
but are not limited to, inconsistent classifications of patient tumours when the tumours 
are subtyped using different types of molecular data, and the efficient integration and 
analysis of different data types to yield consistent identifications of the causal 
disruptors of the molecular processes that underlie the observed differences between 
pancreatic cancer subtypes [192]. Ultimately, these difficulties undermine efforts to 
predict the responses of tumours to drugs: an endeavour involving comparisons 
between the relevant molecular features of a novel tumour with those of well-
characterized tumour subtypes or tumour cell lines.   
With these issues in mind, we attempted to identify clinically relevant subtypes of 
pancreatic cancer accounting for the full spectrum of molecular available for 
pancreatic cancer tumours in the TCGA dataset. We address the problem of 
inconsistent tumour classifications that are obtained using different types of molecular 
data, by applying an integrative classification approach that considered all the 
available molecular data types. As expected, our analyses identified discrepancies 
between various classification schemes but ultimately supported the existence of two 
major pancreatic cancer subtypes. Besides uncovering the likely molecular causes of 
altered biological processes within the tumours of these two subtypes, we identified 
biomarker sets that can be used to accurately and sensitively classify novel pancreatic 
tumours. Further, in the face of multiple high-dimensional data types, we show that 
statistical models that capture the complexity of disease can aid in the identification of 
relevant drugs and drug targets that might offer substantial benefits for patients 
afflicted with tumours belonging to either of the pancreatic cancer subtypes. 
3.2 Results 
3.2.1 Subtypes of pancreatic cancer and their clinical characteristics 
We applied K-means clustering to the reverse phase protein array (RPPA) determined 
proteomics data of the 45 high-purity pancreatic cancer samples that are available in 
the TCGA to identify two coherent clusters of patient tumours [195]. Then, we 
compared this clustering of pancreatic cancer samples to other subtypes that are 
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reported in the literature for various other molecular data types (DNA methylation 
status, protein expression levels and mRNA/ miRNA transcription levels) and 
established that the samples clustered differently depending on the specific molecular 
data type used (Figure 3-1A).  
 
To mitigate this problem, we applied a multi-platform integrative clustering method 
called similarity network fusion (SNF). SNF solves the disparate clustering problem by 
constructing similarity networks of samples for each available molecular data type and 
then efficiently fuses these into one network that represents clustering based on all 
the underlying data types (Figure 3-1B) [192]. Using DNA methylation status, protein 
expression, mRNA transcription and miRNA data of the 45 high purity cancer tumour 
samples available in TCGA, we applied the SNF clustering method to identify two-
cluster and three-cluster clustering solutions (Figure 3-1C).  
 
The pancreatic cancer subtypes in the two-cluster solution comprised 25 and 20 
tumours, which we provisionally named as subtype-1 and subtype-2, respectively.  
Interestingly, the SNF clustering solutions were highly concordant with each of the 
clustering solutions obtained using individual molecular data types but were most 
similar to that obtained using the proteomics data (refer to Figure 3-1C).  
 
Next, we sought to understand whether the identified pancreatic cancer subtypes were 
associated with different clinical outcomes. Indeed, we found that the two groups of 
patients differed with respect to the overall percentages of individuals with progressive 
disease and the percentages of individuals who eventually died. Here we found that 
the patients with subtype-1 tumours were more likely to survive than those with 
subtype-2 tumours (65% vs 35% survival, respectively; Figure 3-2A). We further 
observed a nearly 50% lower median disease-free survival (DFS) period for patients 
with subtype-2 tumours (DFS = 12.42 months) than for patients with subtype-2 
tumours (DFS = 25.07 months; Figure 3-2B). Likewise, the overall survival (OS) 
periods for the patients with subtype-2 tumours (OS = 16.05 months) were shorter 
than those with subtype-1 tumours (OS = 23.06 months; Figure 3-3A). However, our 
analysis of OS and DFS periods using the Kaplan-Meier methods revealed no 
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statistically significant difference between the pancreatic cancer subtypes; possibly 




Figure 3-1: Classification of pancreatic cancer: (A) Comparison between the proteomics-based 
subtyping of pancreatic cancers using unsupervised hierarchical clustering, to other classification 
schemes from top to bottom: TCGA’s (Raphael et al, 2017) miRNA, RPPA, and DNA methylation; 
mRNA-based classification schemes using the gene biomarkers established by Collosson et al; Bailey 
et al; and Moffitt et al.  (B) illustrative example of SNF steps: similarity matrices are used to create 
patient networks from protein, mRNA, miRNA and DNA methylation data showing patient-to-patient 
similarities for the 45 pancreatic cancer patients. The network nodes represent patients. The colours of 
edges joining nodes indicate the degree of similarity between pairs of patients. The nodes of the fused 
network are coloured according to the subtypes to which the patient tumours were assigned using 
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spectral clustering to other classification schemes from top to bottom: TCGA’s [188] miRNA, and DNA 
methylation classifications; mRNA-based classification schemes [94,104]; TCGA’s RPPA classification, 




Figure 3-2: Treatment outcomes: (A) Percentage of total number of pancreatic cancer patients for each 
DFS status after the first course of treatment broken down by the patient’s vital status (dead or alive). 
(B) Kaplan-Meier curve of the disease-free survival months of patients afflicted by each of the 
pancreatic cancer subtypes (C) Kaplan-Meier curve of the overall survival months of patients afflicted 
by each pancreatic cancer subtypes.  
3.2.2 Proteomics-based signalling pathway analyses distinguish disease 
subtypes 
For each disease subtype, we compared the enrichment of KEGG pathways and Gene 
Ontology (GO) biological process classifications of proteins that were upregulated 
within tumour belonging to each of the subtypes using Enrichr [175]. We found that 
whereas certain pathways were differentially altered between tumours belonging to 
different subtypes, other pathways were consistently altered (albeit to different extents 
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in some cases) in the tumours of both subtypes (Figure 3-3A, also see Supplementary 
File 1).  
 
The mTOR signalling pathway was altered in subtype-1 tumours but not in subtype-2 
tumours (combined score = 85, hypergeometric test; p = 2.1 x 10-19). Within the mTOR 
pathway of subtype-1 tumours, we found increased expression of well-documented 
oncogenes including MTOR and BRAF: both of which have previously been linked to 
pancreatic carcinogenesis (Figure 3-3B) [196–198]. 
 
 
Figure 3-3: Pathway enrichment analyses: (A) KEGG pathways enrichment results of the most 
significantly altered pathways in tumours belonging to each of the inferred pancreatic cancer subtypes. 
Refer to supplementary file 1 for the complete list of KEGG pathways enriched based on the proteomics 
data. (B) mTOR signalling pathways found to be uniquely altered in subtype-1 tumours. Blue nodes 
indicate proteins with expression levels that were either not significantly altered between the subtypes 
or were not measured by the TCGA. Red coloured nodes represent proteins with significantly altered 
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expression levels with the degree of statistical significance being expressed as the negative logarithm 
of Benjamin-Hochberg adjusted p-values. The connectivity of network components was extracted from 
the KEA, ChEA, and UCSC super pathway databases. (C) KEGG cancer pathways found to be 
consistently altered in tumours belonging to both pancreatic cancer subtypes. (D) Clustergram of 
tumours using only the proteins that are members of the KEGG cancer pathways ontology. 
 
Further, we found that proteins that are involved in the KEGG cancer pathways were 
dysregulated in both the subtype-1 and subtype-2 tumours; these pathways 
encompass several known oncogenes (such as RAD51, BRAC1, and ERBB2) and 
tumour suppressor genes (such as PTEN and CDK2A1)[199–201] (Figure 3-3C). 
Despite the upregulation of the KEGG cancer pathways in tumours belonging to both 
subtypes, we found that the clustering of patients using only proteins within these 
cancer pathways was concordant with our subtype classification (Figure 3-3D). Such 
a clustering pattern indicates that even when the same pathways are altered both 
subtype-1 and subtype-2 tumours, the exact nature of the alterations within these 
pathways still differs between the two tumour subtypes. For example, whereas 
subtype-1 tumours exhibit hyperactivation of mTOR-associated signalling, subtype-2 
tumours display increased activation of SMAD4-associated signalling. Also, we found 
that other proteins involved in mTOR signalling were both more strongly correlated 
and more highly expressed in subtype-1 tumours than they were in subtype-2 tumours, 
indicating the hyperactivation of this pathway requires the increased expression of 
most of the mTOR signalling proteins (Figure 3-4A). Likewise, SMAD4 signalling 
pathway protein expression levels also differed significantly (p = 2 x 10-4) between 
these subtypes (Figure 3-4B).  
 
We further attempted to identify the kinases that likely phosphorylate substrates within 
the various signalling pathways of pancreatic tumour cells. Using kinase enrichment 
analysis (KEA), we found a subset of kinases that might drive pancreatic 
carcinogenesis, including, among others (Supplementary File 1), AKT1 (p = 8.2 x 10-
03), MTOR (p = 0.011), and RPS6KA1 (p = 0.0499) (Figure 3-4C) [170]. We observed 
a moderate positive correlation between proteins involved in mTOR signalling and 
their phosphorylated forms (Figure 3-4D). Further, our results show that the protein 
phosphorylation pattern among the two pancreatic cancer subtypes is distinctive. 
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Here, we found that in subtype-1 tumours various phosphoproteins that participant in 
mTOR signalling – such as MTOR-pS2448, GSKB-pS21-S9, PDK-pS241 and growth 
factor receptors EGFR-pY1068 and ERBB-pY1248 – all exhibited increased 
phosphorylation (Figure 3-4E) [202,203]. 
 
Figure 3-4: Protein-level differences between pancreatic cancer subtypes: (A) Pearson’s correlation 
values of some proteins involved in mTOR signalling. The plot shows relatively higher expression levels 
of these proteins in subtype-1 tumours compared to subtype-2 tumours. (B) Boxplots shows mTOR and 
SMAD4 protein expression biomarker of the subtypes.  (C) Enriched phosphosites identified by kinase 
enrichment analysis: the negative logarithm values of the Benjamin-Hochberg adjusted p-value are 
plotted on the y-axis while kinases are plotted along the x-axis. The red line represents the cut-off values 
at the 10% false discovery rate. (D) Correlation between the phosphorylated and de-phosphorylated 
proteins species for proteins involved in the mTOR signalling pathway. (E) Unsupervised hierarchical 
clustergram of tumours phosphoproteins showing high concordance with the clustering obtained from 
all the proteins (de-phosphorylated and non-phosphorylated protein) profiled by the TCGA. The 
clustergram was produced using the Spearman correlation distance metric and the complete linkage. 
 
These phosphoproteomics analyses support our initial findings (using 
dephosphorylated proteins) that subtype-1 tumours display increased mTOR 
signalling. Conversely, for subtype-2 tumours, we found elevated phosphorylation 
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levels of proteins such as CDK1-pY15, p27-pT158 and p27-pT198 (Figure 3-4E) which 
are involved in cell-cycle-associated processes [204].  
 
Overall, our findings suggest that for tumours of the two major pancreatic cancer 
subtypes, oncogenesis may be primarily driven by perturbation in either SMAD4 or 
mTOR signalling. 
 
3.2.3 Pancreatic cancer subtypes exhibit functional differences in mRNA 
levels and DNA methylation patterns 
We attempted to determine whether any GO molecular functions were enriched for 
among the overexpressed genes that differentiated the two pancreatic cancer 
subtypes.  Specifically, we queried Enrichr using mRNA transcripts that were 
significantly upregulated across the tumours belonging to each particular cancer 
subtype (see Supplementary File 2) [175]. We found that the over-transcribed genes 
in subtype-2 tumours were enriched for, among others, molecular functions associated 
with transmembrane transporter and G-protein coupled receptor activities (Figure 3-
5A, see Supplementary File 1). Alternatively, the over-transcribed genes in subtype-1 
tumours were enriched for, among others, molecular functions that are associated with 
phosphoinositide 3-kinase signalling, peptidase enzyme activity and growth factor 
receptors (Figure 3-5A, see Supplementary File 1).  
 
We explored the enriched KEGG pathways that were differentially expressed between 
the two pancreatic cancer subtypes using lists of genes with methylation profiles and 
mRNA transcription levels that differed between the subtypes (see Supplementary File 
1). Interestingly, we found that only subtype-1 tumours displayed enrichment for 
pancreatic secretions (Figure 3-5B).  These results corroborate both our previously 
noted enrichment in subtype-1 tumours of mRNAs involved in transmembrane 
transport, and published observations that the secretion of compounds from the 
pancreas and other organs is associated with increased transmembrane transporter 
activity [205].  
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Similarly, for both enrichment analyses using differentially expressed mRNA and 
proteins, we found enrichment for components of the AGE-RAGE signalling pathway 
in subtype-2 tumours (Figure 3-3A and 3-5B). The AGE-RAGE system promotes the 
development of various types of cancers, including those of the pancreas and prostate, 
through diminished apoptosis and increased cell viability [206,207]. Therefore, 
targeted inhibition of RAGE may serve as an effective treatment strategy against 
subtype-2 tumours. 
 
In addition to these findings, the DNA methylation data revealed that while the 
methylation landscapes of subtype-1 and subtype-2 tumours were generally similar, 
the subtype-1 tumours had some additional genes displaying significantly increased 
DNA methylation (Supplementary File 2).  We noted that these hypermethylated 
genes participate in various cellular pathways including focal adhesion, RAP1-
signalling, and actin cytoskeleton regulation (Figure 3-5C). Since these DNA 
methylation alterations are unique to subtype-1 tumours, they could be associated with 
reduced pancreatic tumour aggressiveness.  
 
Unexpectedly, we observed no significant differences in mutation distributions and 
gene copy number alterations for the genes with transcription and translation profiles 
that differed between the two subtypes (Figure 3-5D). 
 
3.2.4 Biomarker genes, proteins and miRNA sets that define the pancreatic 
cancer subtypes 
Given that different types of molecular data yield different patterns of tumour 
clustering, we attempted to identify biomarker genes, proteins or miRNA sets that best 
differentiated between the two pancreatic cancer subtypes. It was anticipated that 
these sets of biomarker genes might allow for consistent classification of pancreatic 
cancer patients using machine learning methods applied to only one category of 
molecular data.  
 
To extract relevant features for each category of molecular data, we applied the 
diagonal adaptation of neighbourhood component analysis (NCA) for classification 
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with regularisation[208]. NCA learns feature weights for minimisation of an objective 
function that measures the average leave-one-out classification loss over the training 
data (Figure 3-9A and 3-9B in the methods section) [208].  
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Figure 3-5: Functional analyses and mutational landscape of pancreatic tumours: (A) Network of Gene 
Ontology (GO) molecular functions found enriched between the two pancreatic cancer subtypes. 
Enrichr was used to obtain enriched GO-terms that were visualised in Cytoscape (refer to the methods 
section). Each node represents a GO-term with similar nodes clustered together and connected by 
edges with the number of shared genes between the nodes being represented by the thickness of the 
edges. The size of each node denotes the gene set size of the represented GO-term. The colour of 
each node represents the magnitude of the combined enrichment score: red represent enrichment in 
subtype-1 tumours and blue represents enrichment in subtype-2 tumours. KEGG pathways: showing 
the top-ranked dysregulated KEGG pathways for each disease subtype based on the (B) mRNA 
transcript levels, (C) and DNA methylation levels. (D) The integrated plot of clinical and molecular 
features of 45 tumour samples ordered by their SNF clustering positions. From top to bottom panels 
indicate: patient gender; Age at which a condition or disease was first diagnosed; neoplasm histological 
grade; SNF subtype of tumour; SMAD4 protein expression level; mTOR protein expression level; 
significantly mutated genes:  TP53, SMAD4 and KRAS gene mutations; SMAD4, CDKN2A and BCL2 
gene deep deletion (dark blue) and shallow deletion (pale blue); gene amplification (red) and copy 
number gain (pink) of multiple genes. 
 
Using NCA, we identified biomarker sets comprising 50 mRNAs, 49 methylated genes, 
14 proteins, and 20 miRNAs. For these biomarker sets, we separately applied 
hierarchical clustering to each of the different molecular data categories to consistently 
and accurately reproduce the pancreatic cancer subtype classifications (Figure 3-7A, 
3-7B, 3-7C and 3-7D). Also, we individually applied supervised machine learning 
methods to the 50 mRNA, and the 49 methylated gene sets to classify tumours into 
subtype-1 and subtype-2 categories. For this, we used the K-nearest neighbour (KNN) 
algorithm for the mRNA expression data and the support vector machines (SVM) 
classifier (see methods section) for the DNA methylation data to achieve very accurate 
subtype classifications of the tumours (Figure 3-7E and 3-7F)[209,210]. Specifically, 
we observed five-fold cross-validation classification accuracies of 99% for the mRNA-
based KNN classifier and 98% for the DNA methylation-based SVM classifier, with an 
agreement of 97% (see methods sections).  
 
Decreasing the number of biomarker genes needed to accurately classify tumours 
from new pancreatic cancer patients would improve the utility of these sets in a clinical 
diagnostic setting. To identify smaller biomarker gene sets, we used supervised 
machine learning methods (see methods section) to define a biomarker set of fewer 
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than ten genes, miRNA or proteins that would minimise incorrect classifications. Also, 
we used these biomarker sets to consistently re-classify TCGA pancreatic cancer 
patients using hierarchical clustering (Figure 3-9 in the methods section). These 




Figure 3-6: Classification of pancreatic tumours using biomarker sets: Clustered heatmap of tumours 
using the (A) mRNA biomarker gene set, (B) DNA methylation biomarker gene set, (C) protein 
biomarker set, and (D) miRNA biomarker set. All the heatmaps (In A, B, C and D) were produced using 
unsupervised hierarchical clustering with the cosine distance metric and complete linkage. The coloured 
bars on each clustergram shows the original subtype classification of each patient’s tumour found by 
applying SNF and spectral clustering to all molecular data sets. (E) Supervised classification of cancer 
patients using the mRNA biomarker set trained on a KNN-model, (F) the DNA methylation biomarker 
set trained on an SVM-model.  For both plots (E and F), t-SNE was used to visualise the tumour classes 
using the exact algorithm and squared Euclidean distance metric. Circled points represent newly 
classified TCGA pancreatic cancer patients, whereas un-circled points represent the original 45 tumour 
samples that were used to train the models. Crossed points represent disagreement between the 
mRNA-based model and the DNA methylation-based model. 
 
To validate the performance of our 50-mRNA biomarker set, we downloaded 
pancreatic cancer data from the ICGC data portal [211]. Using the mRNA-based KNN 
classifier that was trained on TCGA data, we tested the reproducibility of the two-
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subtype classification scheme by classifying 96 ICGC pancreatic cancer patients into 
subtypes-1 and subtypes-2 (Figure 3-8A). We also applied unsupervised hierarchical 
clustering to the mRNA biomarker set extracted from the ICGC RNAseq data to 
reproduce a two-subtype classification analogous to that obtained fusing the TCGA 
datasets (Figure 3-8B). The grouping of ICGC patients yielded by the supervised 
“TCGA classifier” and the unsupervised “ICGC classifier” agreed on the classifications 
of 94% of the patients. We observed that 5% of patients with posterior subtype 
membership probabilities that were less than 0.7, were more likely to be among the 
discordant cases, accounting for five out of the seven discordant patients (Figure 3-
8B) [212].  
 
We examined mutational data for the genes that are frequently altered in pancreatic 
cancer together with the clinical features of subtype-1 and subtype-2 tumours from all 
of the patients represented in the TCGA and ICGC datasets (Figure 3-8C). Here, we 
found no significant differences in the gene mutations between the tumour subtypes 
(see Table 3-1). Also, we observed that no genes were consistently altered in all of 
the tumours belonging to either of the subtypes. Similar to other studies, we 
discovered that some tumours lack mutations in any of the frequently mutated genes 
[213,214]. This diversity in the mutational landscape of pancreatic cancer tumours is 
likely to complicate the discovery of broadly applicable treatment regimens that target 
driver mutations [214].  
 
Concerning histological features of tumours that might be useful for differentiating 
between the subtypes, we observed that only subtype-1 tumours displayed evidence 
of intraductal papillary mucinous neoplasm, whereas only subtype-2 tumours were 
categorised by histological inspection as being pancreatic adenocarcinomas (Figure 
3-8C). Further, we found that subtype-1 tumours tended to be assigned a lower grade 
than subtype-2 tumours (χ2 = 10.3, p < 0.01).  
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Figure 3-7: Biomarker set validation and mutational landscape of pancreatic tumours: (A) Supervised 
classification of ICGC cancer patients using the mRNA-based KNN model trained on TCGA data. 
Circled points represent newly classified ICGC pancreatic cancer patients, whereas un-circled points 
represent the original 45 TCGA tumour samples that were used to train the model. (B) Unsupervised 
hierarchical clustering of the ICGC patients using the mRNA biomarker gene. The coloured bar on the 
clustergram shows the KNN model predicted class. (C) The integrated plot of clinical and molecular 
features for the TCGA and ICGC patient’s data, ordered by their integrative (SNF) clustering. From top 
to bottom panels indicate primary tumour location; neoplasm histological type; patient gender; age at 
diagnosis; neoplasm histological grade; cancer study; integrative tumour subtypes; non-silent gene 
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Table 3-1: Comparison of gene mutations between subtypes 
Gene Chi Square P-Value Adjusted P-Value 
ARID1A 0.333786103 0.563438152 0.843615793 
CDKN2A 1.371503915 0.241553658 0.52336626 
FAT3 3.8986332 0.048325408 0.209410101 
FAT4 1.484768861 0.223029878 0.52336626 
GNAS 0.00044137 0.983238629 0.983238629 
KRAS 1.046475416 0.306320229 0.568880425 
LRP1B 0.078952302 0.778722271 0.843615793 
MUC16 0.25061223 0.616644317 0.843615793 
MUC4 0.085064047 0.770548573 0.843615793 
RNF43 5.837118963 0.0156915 0.101994749 
SMAD4 3.219745336 0.072754948 0.236453581 
TGFBR2 0.105266758 0.745598589 0.843615793 
TP53 6.055228692 0.01386518 0.101994749 
Chi-square test results for the frequently altered genes between the two pancreatic cancer subtypes. 
 
 
3.2.5 Subtyping pancreatic cancer cell lines  
We obtained mRNA expression and drug response data for 45 pancreatic cancer cell 
lines from the Cancer Cell Line Encyclopaedia (CCLE) [7]. We attempted to subtype 
these cell lines using the KNN classifier that we trained on the TCGA mRNA biomarker 
gene set identified using NCA (Figure 3-9A). It is known that cell lines with similar 
transcription profiles are likely to exhibit similar responses to drug perturbations 
[7,215,216]. It follows, therefore, that the drug response profiles of cell lines should be 
predictable based on their gene expression profiles [7,216,217].  
 
3.2.6 Predicting drug responses using machine learning  
Therefore, we predicted the anti-cancer drug responses of the cell lines from the drug 
response profiles of the cell lines that are most similar (i.e., the nearest neighbours) to 
each “query” cell line as determined using an exhaustive KNN searcher model (see 
methods section). The Searcher model quantified and stored information concerning 
similarities between the transcription profiles of all the cell lines. A “query” cell line’s 
nearest neighbours based on squared Euclidean distances were retrieved from the 
Searcher model. To infer the drug response of the query cell line, we calculated the 
median drug response of the retrieved nearest neighbour cell lines to each of the 24 
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anticancer drugs that were profiled by the CCLE (Figure 3-9B). For example, in Figure 
3-9B, the cell lines SU8686 and PANC1005 both have available drug response profiles 
in the CCLE database, and both are the nearest neighbours of the cell line, 
PANC0203. Therefore, we used the mean drug responses of SU8686 and PANC1005 
to predict the drug responses of PANC0203 (see methods section) (Figure 3-9C).  
 
After predicting the drug responses of all the pancreatic cancer cell lines that also had 
measured drug response data in the CCLE database, we compared the predictions to 
the observed drug responses. Our drug response predictions displayed substantial 
agreement with the actual drug responses in that they yielded an average Kappa 
statistic of 0.67 (Figure 3-9D). 
 
 
Figure 3-8: Subtyping pancreatic cancer cell lines and predicting drug responses: (A) Supervised 
classification of CCLE pancreatic cancer cell lines using the mRNA-based KNN-model trained on TCGA 
data. t-SNE was used to visualise the tumour classes using the exact algorithm and squared Euclidean 
distance metric. Circled points represent classified CCLE cell lines, whereas un-circled points represent 
the TCGA samples used to train the models. (B) The t-SNE plot represents the KNN search for the 
nearest neighbours of PANC0203 in the exhaustive searcher model. Refer to the legend at the right 
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bottom of the figure for interpretation. (C) Drug response prediction: first two lanes represent the ranked 
drug responses to the 24 anticancer drugs of the PANC0203 nearest neighbours (PANC1005 and 
SU8686) for which such data is available. The last two lanes represent PANC0203’s predicted drug 
responses and its actual drug responses. (D) Kappa scores of all CCLE pancreatic cancer cell lines 
with drug data. The kappa score was calculated using the quadratic method by comparing the actual 
and predicted drug responses of cell lines to the 24 CCLE anticancer.  
 
3.2.7 Validation of our machine learning drug prediction method using GDSC 
data 
 
To validate the performance of the our Exhaustive search algorithm to predict of drug 
response to pancreatic cell lines profiles by other studies, mRNA expression data 
from 26 pancreatic cancer cell lines together with their response profiles to 309 small 
molecule inhibitors were downloaded from the GDSC database [5]. Then we used 
the 50-mRNA biomarker sets of both the GDSC cell lines and TCGA tumours to 
create an KNN exhaustive searcher model and inferred the response to each cell 
line to the small molecule inhibitors as previously described.  
 
After predicting the drug responses of all the GDSC cancer cell lines that also had 
observed drug response data in the GDSC, we compared the predictions to the 
observed drug responses. Here, our drug response predictions displayed substantial 
agreement with the actual drug responses in that they yielded an average Kappa 
statistic of 0.65, a prediction accuracy that is comparable to the average Kappa 
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Figure 3-9: Kappa scores of all GDSC pancreatic cancer cell lines with drug data. (A)  The kappa score 
was calculated using the quadratic method by comparing the actual and predicted drug responses of 
cell lines to the 309 anticancer drugs. (B) Example drug response prediction plots for the cell lines KP2: 
first two lane(s) represent the ranked drug responses to the 309 anticancer drugs of the nearest 
neighbours (MIAPACA1 and PATU8902) for which drug response data are available. The last two lanes 
represent the predicted drug responses and the actual drug responses. 
3.3 Discussion 
We conducted a comprehensive analysis of clinically relevant patterns of mutation, 
gene methylation, transcription, protein expression, and miRNA synthesis within 
pancreatic tumours. Several studies have previously highlighted the limitations of 
utilising a single molecular data type to accurately classify pancreatic cancers (Figure 
3-1A) [185,186,188,218]. Here, we attempted to resolve this issue by employing a 
multidimensional clustering method capable of simultaneously utilising protein 
expression, mRNA transcription, DNA methylation and miRNA synthesis data. We 
found that by integrating across all these molecular data types, pancreatic cancer 
tumours could be classified into two clinically distinct subtypes: which we have simply 
named subtype-1 and subtype-2. 
 
We observed that subtype-1 tumours were characterised by alterations of the mTOR 
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were positively correlated to each other (Figure 3-4A, 3-4B and 3-4D). This finding is 
consistent with previous studies based on analyses of mRNA transcription and 
mutation data which also observed alterations of the mTOR pathway in pancreatic 
cancers [219–221]. Further, it is well established that some pancreatic cancer 
subtypes respond well to drugs which inhibit the mTOR pathway [222,223]. 
Accordingly, we anticipate that subtype-1 tumours will likely be more responsive to 
such therapies than will subtype-2 tumours.  
 
Interestingly, subtype-2 tumours display unique alterations to cell cycle pathways 
(Figure 3-3A).  This is consistent with the observation that subtype-2 tumours are 
clinically more aggressive than subtype-1 tumours in that an element of 
aggressiveness is the hyperactivation of the cell cycle processes that accelerate 
tumour growth [224–227].   
 
We noted that, in addition to differences in patterns of protein expression, the two 
pancreatic cancer subtypes differ with respect to patterns of protein phosphorylation, 
implying that the kinases that are involved in oncogenic transformation differ between 
the subtypes. Specifically, whereas subtype-1 tumours show upregulation of mTOR 
signalling associated kinases (among others, MTOR-pS2448, GSKB-pS21-S9, and 
PDK-pS241), subtype-2 tumours display upregulation of cell cycle associated kinases 
(among others, CDK1-pY15, p27-pT158, and p27-pT198; Figure 3-4). Most of these 
kinases represent credible targets for small molecule inhibitors that might prove useful 
for subtype-specific anticancer therapies. Such small molecule kinase inhibitors are 
currently either being tested in clinical trials or are already in use as cancer therapies 
[227–230].  
 
In addition to displaying alterations in the mTOR signalling pathway, subtype-1 
tumours also display evidence of elevated ion channel (Figure 3-5A) and secretion 
pathway activities: a phenotype that is likely associated with increased trans-
membrane transport of cell products (Figure 3-5B). Changes in the expression 
patterns of ion channel proteins are also found in breast and prostate cancers 
[231,232]. In pancreatic cancers, ion channel proteins likely play crucial roles in 
  67 
cellular processes that are integral to oncogeneses such as cellular proliferation, 
motility, tissue invasion, and the excretion of lactic acid produced as a consequence 
of anaerobic respiration [233,234]. It is plausible therefore that subtype-1 tumours may 
be responsive to anti-cancer treatments that target ion channels and membrane pump 
proteins [233]. 
 
Subtype-2 tumours on the other hand display elevated peptidase activities (Figure 3-
5A). Peptidases regulate various proteins that play essential roles in regulatory 
signalling networks.  As is presently the case for tumours of the kidney, peptidases 
may be useful as diagnostic and/or prognostic biomarkers of subtype-2 pancreatic 
cancers [235,236].    
 
We found no significant differences in the mutational landscape between the two 
pancreatic cancer subtypes, indicating that the accumulation of similar genetic 
mutations drive the formation of tumours belonging to both subtypes. Recently, the 
paradigm of oncogenesis has been expanded beyond the classical view that 
oncogenesis is entirely driven by the accumulation of genetic mutations [155,237]. This 
paradigm now includes the disruption of epigenetic regulatory mechanisms and 
variations in miRNA expression [237–242]. Unlike with mutations, we currently lack 
adequate conceptual knowledge and the analytical framework needed to identifying 
putative driver and passenger changes in epigenetic and miRNA based regulatory 
processes [74–76].  
 
Nevertheless, we observed several differences between subtype-1 and subtype-2 
tumours with respect to epigenetic (DNA methylation profile) and miRNA signatures. 
These suggest that epigenetic and/or miRNA variations may be primarily drivers of the 
differences in the transcriptome and proteome profiles of subtype-1 and substype-2 
tumours. 
 
In line with other studies that have identified biomarkers to classify tumour subtypes, 
some of which have important treatment and prognostic implications, we identified 
biomarker mRNA, DNA methylation,  protein or miRNA sets that could be used to 
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accurately subtype pancreatic tumours [185,186,218,246].  We are optimistic that any 
of these four biomarker sets could be individually used to obtain accurate subtype 
classifications for new pancreatic tumours. Nevertheless, the utility of these four 
biomarkers sets for predicting clinical outcomes and guiding treatment strategies will 
need to be evaluated in future studies.  
 
Encouragingly, we were able to demonstrate that, by focusing on just the transcription 
levels of the mRNA molecules that are represented in our mRNA biomarker set, we 
could accurately predict the drug responses of cell lines based on the drug responses 
of other cell lines with similar mRNA expression profiles. Although others have also 
been able to predict the drug responses of cell lines using similar machine learning 
approaches [7,187,216,217,247], our approach is novel in that it utilizes tumour 
subtyping based on all available molecular data to mine for biomarkers that 
differentiate disease subtypes: biomarkers which are then used to inform our KNN 
exhaustive search model with respect to quantifying the similarity of cell lines. What 
this means is that our approach is capable of utilizing matched molecular data and 
drug responses from either cancer patients or cell lines to predict, with reasonable 
accuracy, the drug responses of tumours for which we have only information on the 
concentrations of the mRNAs, proteins or miRNAs that are included within the 
biomarker sets which we have identified. As with other machine learning based 
inference schemes, the accuracy of the predictions that are made should improve 
given additional matched molecular and drug response data [248].  
 
Altogether, our analyses have revealed the molecular underpinnings of, and potential 
treatment strategies for, two clinically distinct forms of pancreatic cancer. We are 
optimistic that an approach such as we have used, where multiple different molecular 
data types are leveraged to subtype and characterise particular tumour variants, could 
yield valuable insights into the management of other difficult to treat cancers such as 
those of the lungs and triple negative breast cancer.    
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3.4 Methods 
We analysed data from 185 of the pancreatic cancer patients who had contributed 
samples to the TCGA project [96]. Data on these patient samples within the TCGA 
included:  reverse phase protein array-based proteomics data (RPPA; n = 45), whole 
exome sequencing data (n = 76), transcriptome data determined using RNAseq (n = 
76); DNA copy number and mutation data (n = 76), miRNA data (n= 56), and 
comprehensive clinical data.  For our analyses, we only considered the 76 “high purity” 
samples for which transcriptome and whole exome sequencing data was available. 
Out of these 76 samples only 45 have RPPA data. All data used in our analyses were 
obtained from cBioPortal (http://www.cbioportal.org)[50]. 
 
3.4.1 RPPA-based classification of pancreatic cancer  
K-means clustering of proteomic data was performed to identify subtypes of the 45 
high purity TCGA pancreatic tumour datasets with available RPPA data [209]. To find 
the most informative number of clusters, K-means clustering was run over 500 
iterations for cluster sizes (K values) of two, three, four, and five (i.e., K = 2 to 5). The 
average silhouette values for each value of K were compared, revealing that the two-
cluster solution had the highest mean silhouette value and was therefore deemed to 
be the most coherent (Figure 3-9A).  To aid in visualizing the most informative features 
that differentiated between the two inferred tumour subtypes, the 112 proteins with the 
highest entropy values across samples were used to reproduce the two-cluster K-
mean classification using semi-supervised hierarchical clustering (Figure 3-1A) [249]. 
The clustering pattern thus obtained was visualised using a principal component 
analysis plot (Figure 3-9B) [250]. The clustering of these 45 pancreatic cancer tumours  
based on protein, miRNA and DNA methylation data has been previously published 
by Raphael et al [188], and the results of these clustering analyses were extracted 
from the supplementary file of that publication. 
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Figure 3-10: K-mean clustering plots: (A) Choosing the number of clusters: plots of Silhouette values 
for each value of K (number of clusters). (B) Visualisation of the K-means clustering of the 45 high-
purity pancreatic tumours. Principle component analysis was used to reduce the proteomic data 
dimensions, and the first two principal components plotted on the x-axis and y-axis, respectively. 
 
3.4.2 Integrative subtyping of pancreatic cancer 
Similarity Network Fusion (SNF) is a clustering method that considers information from 
multiple molecular profiles. It has previously been used to segregate tumours of 
various cancer types based on multiple different sources of molecular data [192]. 
Briefly, standard normalised protein, mRNA, miRNA, and DNA methylation data 
derived from the 45 high-purity samples were used to create patient similarity networks 
(Figure 3-1B). Next, we ran SNF to fuse the similarity networks over 25 iterations, with 
hyperparameter settings of 24 and 0.7 for the number of neighbours and alpha value, 
respectively. Finally, spectral clustering with two specified as the best number of 
clusters (identified according to the eigengap) was applied to the unified similarity 
network to obtain the final tumour classification (Figure 3-1C) [192].  
 
3.4.3 Patient’s clinical characteristics of the pancreatic cancer subtypes  
The Kaplan-Meier method was used to compare overall survival and the duration of 
progression-free survival of patients with tumours belonging to the different pancreatic 
cancer subtypes [160].  
3.4.4 Pathways and kinase enrichment analyses 
The differentially expressed proteins between the pancreatic cancer subtypes were 
identified using the Student t-test with unequal variance and with the Benjamin-
Hochberg correction applied to p-values [251,252].  Further, we queried Enrichr with 
two lists of 60 and 30 proteins found to be upregulated in subtype-1 and subtype-2 
C=2 C=3 C=5C=4
A B
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tumours, respectively, to return enriched KEGG pathways for each subtype (see 
Supplementary File 1) [39,175]. The enriched KEGG pathways were compared to 
identify pathways that are unique to each of the disease subtypes [11]. The proteins 
that participate in pathways that are uniquely altered in sybtype-1 or subtype-2 
tumours were used to construct protein-protein interaction networks using known 
interactions from each of the following databases: the University of California Santa 
Cruz Super pathway (101,525 protein-protein interactions), the Kinase Enrichment 
Analysis (428 kinases and their 10,792 targets), and Chromatin Immunoprecipitation 
Enrichment Analysis 2016 (667 transcription factors and their 464,967 targets) 
[169,170,253]. We visualised the resulting networks in yEd (Figure 3-3B and Figure 3-
3C). Lastly, Kinase Enrichment Analysis was used to computationally identify the 
kinases that are responsible for the observed phosphorylation patterns in pancreatic 
cancer [170]. 
 
The moderated student t-test based on the negative binomial model was used to 
identify differentially expressed mRNAs and variations in DNA methylation patterns 
(see Supplementary File 2) [254,255]. Additionally, functional enrichment analyses 
were performed using lists of differentially expressed mRNA transcripts or altered DNA 
methylation patterns associated with each disease subtype. These were used to query 
Enrichr to return Gene Ontology (GO) molecular functions and KEGG pathways 
enriched for each disease subtype (Figure 3-1B, Figure 3-1C, and see Supplementary 
File 2). A custom MATLAB script was used to create an enrichment network based on 
the enriched GO-molecular function designations. This enrichment network was 
visualised in Cytoscape (Figure 3-5A) [256].  
 
3.4.5 Identification and evaluation of biomarker sets 
We used various data mining and machine learning methods to identify biomarker sets 
of mRNAs, DNA methylation, miRNAs or proteins that individually and consistently 
best stratified the two pancreatic cancer subtypes. The diagonal adaption of 
neighbourhood component analysis (NCA) with regularisation method was used to 
select the most useful features for each molecular data type (Figure 3-10A and 3-10B) 
[208]. Briefly, NCA attached feature weights to each attribute where the feature 
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weights are used to select the most important attributes for classification. For each 
molecular biomarker dataset identified using NCA, unsupervised hierarchical 
clustering was applied to the TCGA datasets to reproduce the two-subtype pancreatic 
cancer classification (Figure 3-6A, 3-6B, 3-6C and 3-6D). To apply supervised 
machine learning methods that accurately predict the tumour subtypes while utilising 
only one molecular data type, 23 different machine learning classifiers were trained 
ranging from linear discriminate analysis, support vector machines, decision trees, 
logistic regression, ensemble trees, and K-nearest neighbour algorithms. Then, the 
best performing classifier for each molecular biomarker dataset was selected based 
on their 5-fold cross-validation accuracy and area under the receiver operating 
characteristic curve (Table 3-2). The selected models were the cubic K-nearest 
neighbour for the mRNA biomarker set (98.7% accuracy), quadratic SVM for the DNA 
methylation biomarker set (97.8% accuracy), Ensemble bagged trees for the protein 
biomarker set (95.6%), and the course Gaussian SVM for the miRNA biomarker set 
(93.3% accuracy) [257].  
 
 
Table 3-2: Trained supervised learning models 
Genetic Data Biomarker Size Best Algorithm  Accuracy  AUC 
mRNA 50 Cubic KNN  98.4%  0.99 
Protein 14 Ensemble Bagged Trees  95.1%  0.97 
Methylation  49 Quadratic SVM  97.6%  0.99 
microRNA 20 Course Gaussian SVM 93.3%  0.95 
Machine learning models that were trained for each biomarker genes, proteins and miRNA. All models 
were training using 5-fold cross-validation, and the best performing models were selected based on the 
classification accuracy, and the curve area under the curve. 
 
To improve the accuracy of these models, the optimal hyperparameters that minimise 
the five-fold cross-validation loss were obtained using Bayesian hyperparameter 
optimisation (Figure 3-10C and 3-10D) [258–260]. This improved the overall 
classification accuracy of the models on the cross-validation set to 100% for the 
mRNA-based KNN model and 99% for the DNA methylation-based SVM model. The 
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trained models were then used to classify 31 other high-purity pancreatic tumours from 
the TCGA (Figure 3-6E and 3-6F). Supervised learning models based on the 
proteomic or miRNA biomarkers datasets were not trained because there were too 
few other high purity samples profiled by TCGA for these data types. Further, for each 
molecular data biomarker set, between three and ten features were selected based 
on the lowest cross-validation loss of the best performing algorithm (Figure 3-10E). 
These features were then used to classify TCGA pancreatic cancer samples using 
unsupervised hierarchical clustering (Figure 3-10F, 3-10G, 3-10H and 3-10I).  
 
 
Figure 3-11: Feature selection and machine learning classification of pancreatic cancer: (A) Identifying 
the best regularisation value (lambda) for NCA: plot of average loss values vs the lambda values of 
classification. In this example, the best lambda value that corresponds to the minimum average loss for 
the protein features was 0.1203. (B) A plot of learned feature (protein) weights using NCA of the proteins 
in the RPPA data that would be used to classify patients into the two integrative subtypes. The weights 
of the irrelevant features are close to zero. (C) Plot showing the selected optimal machine learning 
hyperparameters using Bayesian optimisation for the mRNA-based KNN model. On the x-axis are the 
number of neighbours, y-axis the distance metric and the z-axis average model loss. The optimal value 
is shown by the red star, i.e., one neighbour and the squared Euclidean distance. (D) Plot showing the 
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methylation-based SVM model. On the x-axis is the box constraint, the y-axis is the SVM kernel scale 
and estimate average model loss on the z-axis. The optimal values are shown by the red star; box 
constraint of 0.46 and kernel scale of approximately 0.02. (E) The number of features plotted against 
the average loss value of each supervised learning model for the Molecular data. The best in the top 
ten features that may be used to reproduce the integrative classification were selected based on the 
best loss (circled point). (F) Clustered heatmaps of the selected five mRNA transcripts, (G) four DNA 
methylation gene, (I) six proteins and (J) eight miRNAs: plots were produced using unsupervised 
hierarchical clustering with the correlation distance metric and the complete linkage. 
 
3.4.6 Validating biomarker molecular datasets 
To evaluate the performance of the biomarker mRNA on a different pancreatic cancer 
dataset, we downloaded pancreatic cancer data from the ICGC data portal [9]. From 
the initial 50 mRNA biomarker set identified using the TCGA dataset, only 45 had 
corresponding data in the ICGC mRNA dataset. Therefore, we extracted the 45 gene 
biomarker set from both the TCGA and ICGC data. The mRNA-based KNN model was 
then re-trained on the TCGA 45 mRNA biomarker set. Here, standard normalisation 
was applied as a pre-processing step both to avoid platform associated biases, and 
because it was previously performed on the data before SNF clustering.  Thereafter, 
the TCGA mRNA-based KNN model was used to predict the subtype of tumours in 
the ICGC dataset using a standard normalised mRNA biomarker set that we extracted 
from the ICGC RNAseq data (Figure 3-7A). Also, unsupervised hierarchical clustering 
was applied to the ICGC biomarker gene set (Figure 3-7B).  Finally, the mutational 
landscape and clinical characteristics of the two pancreatic cancer subtypes of both 
the ICGC and TCGA datasets were compared (Figure 3-7C).  
 
3.4.7 Subtype classification of cell lines  
mRNA expression data from 45 pancreatic cancer cell lines together with their 
response profiles to 24 anticancer drugs were downloaded from the Cancer Cell Line 
Encyclopaedia [7]. The 50-mRNA biomarker set was extracted from the mRNA 
expression dataset and standard normalised. Then, the normalised CCLE mRNA 
biomarker genes were to subtype the cell lines by running the mRNA transcript levels 
for these genes through the mRNA-based KNN-model trained on TCGA data.  The 
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predicted subtypes of the CCLE cell lines were visualised using t-distributed stochastic 
neighbour embedding (t-SNE; Figure 3-8A).  
 
3.4.8 Machine learning method to predict a cell line’s drug response  
An exhaustive nearest neighbour searcher model was created using standard 
normalised mRNA biomarker sets of both the CCLE cell lines and TCGA tumours 
[261]. The exhaustive searcher model takes as input the training data (in this case the 
mRNA biomarker set), distance metrics, and parameter values of the distance metrics 
for an exhaustive nearest neighbour search and can then be used to identify the 
nearest neighbours to a particular patient tumour or cell line within a specified radius 
of the distance matric. Here, the nearest neighbours to a particular cell line suggest 
similarity at the molecular level based on mRNA, DNA methylation, protein and miRNA 
data encoded in the SNF subtyping. The ten nearest neighbouring cell lines or tumours 
were determined using a nearest neighbour search algorithm based on a Euclidean 
distance metric (see Figure 3-8B for intuition). After that, the drug response activity 
areas of the nearest neighbour cell lines were z-normalized and categorised as 
sensitive (for z-scored activity areas >0.8), intermediate (for z-scored activity areas 
between 0.8 and -0.8), or resistant (for z-scored activity areas <-0.8). A simple 
prediction model was employed where the median responses to a particular drug of 
the nearest neighbouring cell lines was used to infer a target cell line’s drug response 
(Figure 3-8B and 3-8C). Following this the quadratic Cohen’s Kappa score was used 
to evaluate the goodness of fit between the predicted and the actual drug response 
profiles of the cell lines (Figure 3-8D) [262].  
 
3.4.9 Validation of our machine learning drug prediction method using GDSC 
data  
mRNA expression data from 26 pancreatic cancer cell lines together with their 
response profiles to 309 small molecule inhibitors were downloaded from the GDSC 
database [5]. The 50-mRNA biomarker set was extracted from the mRNA expression 
dataset and standard normalised.  
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Next, described for predictions made using the CCLE dataset, an exhaustive nearest 
neighbour searcher model was created using standard normalised mRNA biomarker 
sets of both the GDSC cell lines and TCGA tumours [261]. The 8 nearest neighbouring 
cell lines or tumours were determined using a nearest neighbour search algorithm 
based on a squared Euclidean distance metric (refer to Figure 3-8A and 3-8B for 
intuition). Then we used the predicted the response of each GDSC cell line to each of 
the 309 small molecule inhibitors using the methods previously described in section 
3.2.5.  
 
3.4.9 Statistical analyses  
All statistical analyses were performed in MATLAB 2018a except where stated 
otherwise. Fisher's exact tests were used to assess associations between categorical 
variables.  Wilcoxon rank sum tests or independent sample Student t-tests were used 
for continuous variables where appropriate. Statistical tests were considered 
significant at p < 0.05 for single comparisons, and for Benjamini-Hochberg adjusted p-
values < 0.05 for multiple comparisons. 
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Chapter 4 : Metabolic Genes Alterations Impacts the Clinical 
Aggressiveness and Drug Response of 32 Human Cancers  
This section is a reformatting of a paper published in Communications Biology [263]: 
https://www.nature.com/articles/s42003-019-0666-1 
Musalula Sinkala, Nicola Mulder, Darren Martin 
4.1 Introduction 
The transformation of normal cells into cancer cells requires the adaptation of multiple 
metabolic processes to satisfy the high energy demands of malignant cellular growth, 
proliferation and survival [264,265]. Accordingly, metabolic dysregulation is 
recognised as a hallmark of malignant cellular phenotypes [155,266]. Although many 
of the metabolic processes occurring in cancer cells are similar to those occurring in 
healthy proliferating cells, a series of genetic and epigenetic modifications in cancer 
cells can result in the aberrant regulation of these processes [267,268]. Among these 
genetic alterations are those occurring in a range of genes that are involved in 
metabolism. These alterations include diverse “driver” mutations and gene copy 
number alterations, which can impart a substantial degree of metabolic heterogeneity 
to different tumours of the same cancer type [269]. There is, therefore, keen interest 
in determining how genetic alterations within various types of malignant cells relate to 
specific aspects of the metabolic dysregulation occurring within these cells.  
  
Transcriptomic and metabolomic analyses of various human tumours have revealed 
the numerous metabolic peculiarities of cancer cells that likely play essential roles in 
oncogenesis and cancer progression [269–274]. In general, these peculiarities can be 
traced to abnormal variations in the expression levels of either particular metabolic 
enzymes or the proteins that regulate these enzymes [114,275]. These and other 
studies [264,266,268,276–280] have also yielded a growing appreciation of how the 
aberrant metabolic changes in cancer cells influence the anticancer drug responses 
of different tumours.  
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Besides enabling the selection of the most appropriate available drugs, a better 
understanding of the metabolic differences between different cancer cell types will also 
likely yield better disease outcome predictions. This is because some of the metabolic 
features of cancer cells are likely to be directly associated with disease 
aggressiveness and clinical outcomes [281–283].  
 
Until recently, a major impediment to linking specific metabolic dysregulations in 
cancer cells to particular disease outcomes or drug responses has been that the 
relevant metabolic pathways and their participating proteins were only partially known. 
The effective leveraging of detectable metabolic dysregulation to achieve either 
accurate prognosis or actionable treatments was further hampered by the 
unavailability of both large numbers of genomic/transcriptome datasets for the 
tumours of cancer patients with known clinical features and outcomes, and consistent 
data on the drug response profiles of large numbers of different human cancer cell 
types. 
 
Today, however, comprehensive pathway curation projects (such as, for example, the 
Reactome and KEGG pathway projects) have successfully gathered high-quality 
information on human metabolic proteins and has accurately mapped these to 
metabolic pathways [10,11]. Cancer profiling projects such as that carried out by The 
Cancer Genome Atlas (TCGA) have yielded detailed genetic, transcriptomic, 
proteomic, and epigenetic data for thousands of human tumours each of which is 
annotated with clinical information for the patient from which it was taken [8]. Analysis 
of the TCGA data in the context of our present understanding of human metabolism 
should both illuminate the metabolic differences between different cancer types, and 
identify which of these differences has the most meaningful prognostic value. If this 
information is then coupled with the known drug responses of different cancer cell 
types, it should also be possible to identify the most suitable drugs to treat any 
particular cancer.    
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In this regard, large-scale drug response screening projects are extremely valuable. 
The immortalised human cell lines that have been widely applied as models of 
human disease can also be used for both drug discovery and the evaluation of drug 
dependencies [85,225,231]. For example, the Genomics of Drug Sensitivity in 
Cancer (GDSC) project, has provided genetic, transcriptome and epigenetic profiles 
for over one thousand human cancer cell lines together with their dose-response 
profiles to hundreds of anticancer drugs [5]. The genetic, transcriptomic and 
epigenetic profiles of tumour samples from the TCGA and those of cancer cell lines 
from the GDSC can be directly compared to systematically test for metabolic 
similarities and differences that might have a bearing on drug responses. More 
specifically, the subset of the cancer cell lines that have genomic and transcriptomic 
features that are most similar to those of tumour cells from a patient could be used 
to interrogate how metabolic perturbations in the patient’s tumour cells are likely to 
influence the effectiveness of particular anticancer drugs.    
 
Here, we used data on mutations and copy number variations from the TCGA in 
conjunction with Reactome Pathways data to identify the heterogeneous metabolic 
features of 32 human cancers. We then used these features together with drug 
response data from the GDSC to identify specific metabolic perturbations in tumour 
cells that are likely to impact their responses to different anticancer drugs.  
 
4.2 Results 
We analysed a TCGA dataset comprising lists of gene alterations (mutations and copy 
number variations) together with clinical information collected from 10,528 patients 
afflicted by 32 different human cancers (Figure 4-1A). Also, we analysed lists of gene 
alterations found within the genomes of 812 human cancer cell lines together with the 
drug-response profiles of these cell lines to 251 anticancer drugs to reveal 
associations between gene alterations and drug responses.  
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4.2.1 Alterations to genes involved in metabolism distinguish human cancers 
We obtained curated human metabolic pathway data and the names of genes involved 
in these pathways from the Reactome Pathways database using the annotation 
search term “metabolism” (see https://reactome.org/PathwayBrowser/#/R-HSA-
1430728) [10]. In this database, the term “metabolism” encompasses 68 different 
metabolic pathways involving 2,325 genes. Within the TCGA dataset, we found that 
out of these 2,325 genes, 2,095 contained an alteration in at least one of the 10,225 
analysed patients. 
 
Among the 2,095 metabolic genes displaying some alteration (a copy number variation 
or a mutation) in at least one patient, the most frequently altered were PIK3CA in 1,384 
individual tumour samples, APOB in 976 and LRP2 in 961 (Figure 4-1B). Most of the 
genes displaying some alterations in tumours of different cancer types have well-
defined roles in carcinogenesis. For instance, mutations of PIK3CA reprogram 
metabolism and are associated with poorer survival outcomes in several cancers, 
including those of the colon, rectum, breast and lungs [284–287]. APOB is a lipid 
metabolism regulator that is linked to carcinogenesis and tumour progression in the 
liver, lungs and other tissues [288–290]. LRP2 encodes a low-density lipoprotein 
receptor-related protein-2 which mediates endocytic uptake of various lipids, is linked 
to the enhanced metabolism of lipids and vitamin D, and promotes the transformation, 
proliferation and survival of various types of cancer cells [291–293].   
 
Next, we calculated the frequency of alterations among the 16 first-tier metabolic 
pathways across all 32 of the cancer types. Here we found that genes involved in lipid 
metabolism were the most commonly altered, followed by those involved in 
carbohydrate metabolism and then those involved in amino acid metabolism (Figure 
4-1C). These findings echo the well-established tenet of molecular oncogenesis, that 
meeting the cellular energy and biosynthetic demands of malignancy require 
alterations to the lipid, carbohydrate and amino acid metabolic pathways [266,280].  
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Figure 4-1: Mutational landscape of TCGA tumours: (A) Distribution of 10,528 TCGA tumours across 
32 human cancer types broken down by tissue of origin. TCGA disease codes and abbreviations: 
UCEC, uterine corpus endometrial carcinoma; SKCM, skin cutaneous melanoma; BLCA, bladder 
urothelial carcinoma; UCS, uterine carcinosarcoma; OV, ovarian serous cystadenocarcinoma; LUSC, 
lung squamous cell carcinoma; STAD, stomach adenocarcinoma; LUAD, lung adenocarcinoma; ESCA, 
oesophageal adenocarcinoma; DLBC, diffuse large b-cell lymphoma; CESC, cervical squamous cell 
carcinoma; HNSC, head and neck squamous cell carcinoma; SARC, sarcoma; LIHC, liver 
hepatocellular carcinoma; BRCA, breast invasive carcinoma; COADREAD, colorectal adenocarcinoma; 
CHOL, cholangiocarcinoma; ACC, adrenocortical carcinoma; PAAD, pancreatic adenocarcinoma; 
PRAD, prostate adenocarcinoma; GBM, glioblastoma multiforme; KIRP, kidney renal papillary cell 
carcinoma; KIRC, kidney renal clear cell carcinoma; MESO, mesothelioma; LGG, brain lower grade 
glioma; UVM, uveal melanoma; PCPG, pheochromocytoma and paraganglioma; TGCT, testicular germ 
cell tumours; KICH, kidney chromophobe; THYM, thymoma; LAML, acute myeloid leukaemia; THCA, 
thyroid carcinoma. (B) Genes involved in metabolism found to be most altered across all human 
cancers. (C) Clustered heatmap of cancer types using the percentage of tumours with first-tier 
metabolic pathway genes displaying alterations. Pathways are ordered by decreasing frequencies of 
alterations. Increasing colour intensities denote higher percentages. The heat map was produced using 
unsupervised hierarchical clustering with the Euclidean distance metric and complete linkage (see 
Tissue of Origin
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  6 
Figure 4-10). The bar graph represents the fraction of tumours with either mutations or copy number 
variations in each cancer type and metabolic pathway. The coloured bars on the heatmap show the 
tissue of origin for each cancer: 1 = Breast; 2 = CNS, 3 = Endocrine; 4 = Eye; 5 = GI tract; 6 = 
Gynecologic; 7 = Haematologic & Lymphatic; 8 = Head & Neck; 9 = Skin; 10 = Soft Tissue; 11 = 
Thoracic; 12 = Urologic. The bar graph represents the overall frequency of genomic alterations in each 
human cancer.  
 
We clustered the 32 human cancers based on the frequencies of genomic alterations 
of metabolic pathways. Our clustering revealed two major groups of cancers (Figure 
4-9 in the methods section): those cancers with a higher frequency of metabolic gene 
alterations (which we named as HM; n = 6,191) and those with a lower frequency of 
metabolic gene alterations (named as LM; n = 3,329). Interestingly, we observed that 
the landscape of metabolic gene alterations varied across the 32 cancer types. The 
median alteration frequencies for genes involved in each of the 16 first-tier metabolic 
pathways was higher in skin cutaneous melanoma (occurring in 90% of patients with 
this type of cancer) and lung squamous cell carcinoma (occurring in 84% of patients), 
whereas only 21% of patients with acute myeloid leukaemias and 14% of patients with 
thyroid carcinomas exhibited metabolic gene alterations (Figure 4-1C).  
 
We examined whether the HM and LM cancer supertypes were associated with 
different clinical outcomes. Remarkedly, we observed that the median disease-free 
survival (DFS) periods was significantly lower (p = 1.3 x 10-7; log-rank test [160]) for 
the HM cancer patients (median = 58.3 months) than it was for the LM cancer patients 
(median = 116.2 months; Figure 4-2A). Similarly, the duration of overall survival (OS) 
periods for the HM cancer patients (OS = 68.9 months) were significantly shorter (p = 
6.8 x 10-10) relative to those of the LM cancer patients (OS = 116.2 months; log-rank 
test; Figure 4-2B). We validated these findings with an independent dataset of patients 
afflicted with various cancers from the ICGC databases [9]. As with the patients 
recorded in TCGA the median OS period for patients recorded in the ICGC databases 
who had cancers belonging to the HM supertype (OS = 1,759 days) was significantly 
lower (p = 6.3 x 10-17) than that of patients with cancers belonging to the LM supertype 
(OS = 3,681 days; Figure 4-2C). Our results, therefore, demonstrate an association 
between the extent to which metabolic genes in cancer cells are altered (and therefore 
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probably the degree of metabolic dysregulation within these cells), and the 
aggressiveness of cancers.  
 
 
Figure 4-2: Disease outcomes of the HM and LM tumours: Kaplan-Meier curve of the disease-free 
survival periods (A) and overall survival periods (B) of TCGA patients afflicted by the HM and LM cancer 
supertypes. (C) Kaplan-Meier curve of the overall survival periods of ICGC patients afflicted by the HM 
and LM cancer supertypes. 
 
There is noteworthy, however, that when we separately examined each of the 32 
cancer types in isolation and compared the clinical outcomes of patients with tumours 
displaying higher and lower numbers of metabolic gene alterations, we detected no 
statistically significant difference in the duration of the DFS and OS periods for any of 
the 32 cancer types other than adrenocortical carcinomas (supplementary file 2). 
 
4.2.2 Alterations of genes involved in carbohydrate, amino acid and lipid 
metabolic pathways across all cancers 
We evaluated the extent of alterations to genes involved in second-tier lipid, 
carbohydrate, and amino acid metabolic pathways as these pathways had the highest 
gene alteration frequencies across all 32 of the cancer types (Figure 4-1C). We found 
that, as with the genes involved in the first-tier pathways, alterations to genes involved 
in second-tier pathways were more frequent in the HM cancers than in the LM cancers 
(Figure 4-3). Among the genes involved in second-tier carbohydrate metabolism 
pathways, those involved in the glycosaminoglycan metabolism (in 67% of all patients’ 
tumours) and glucose metabolism (in 58% of tumours) pathways were the most 
commonly altered across all cancers. In recent years, cellular glycosaminoglycan 
profiles have been shown to be markedly altered during tumour pathogenesis and 
progression. Glycosaminoglycans influence cell signalling, angiogenesis, tumour 
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invasiveness, and metastasis, and have therefore emerged as essential 
pharmacological targets for the treatment of cancer  [294–296].  
 
 
Figure 4-3: Frequency of tumours of different cancer types with altered genes that are involved in 
second-tier metabolic pathways of carbohydrate, lipid and amino acid metabolism. The cancers are 
arranged according to how they clustered based on similarities between their first-tier metabolic 
pathway gene alterations (as in Figure 4-1C). Increasing colour intensities denote higher percentages 
of tumours with gene alterations).  
 
Among the genes involved in second-tier amino acid metabolism pathways, those 
involved in selenoamino acid metabolism (in 56% of all patients’ tumours) and 
polyamine metabolism (in 56% of tumours) were the most altered across all the 
cancer types. Increased polyamine metabolism is associated with neoplasia: an 
important risk factor for the development of cancer in humans [297–301]. Drugs that 
target polyamine metabolism, several of which are in clinical trials, have been 
considered for the treatment of many cancers, including those of the colon, prostate, 
and skin [297,298,302]. Unlike with polyamines, the roles of selenoamino acids in 
cancer remain poorly explored; although an enrichment of selenoamino acids has 
been noted in breast cancer cells [303]. We anticipate that studying alterations of 
selenoamino acid metabolism could yield targets for the development of new 
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therapeutics and predictive biomarkers that would aid the treatment of various 
cancers. 
  
Abnormal lipid metabolism has emerged as a metabolic hallmark of oncogenesis 
and tumour progression [304]. Here, we found that across all cancers, the most 
frequently altered of the lipid metabolism genes were those involved in the 
phospholipid metabolism (in 79% of all patients’ tumours) and fatty acid metabolism 
(in 68%). Changes in the transcripts of genes that encode membrane phospholipids 
and the actual levels of phospholipids have been shown in various cancers, 
including those of the breast and lung [305–307]. Since the changes in phospholipid 
metabolism can affect the proliferation of cancer cells and their responses to drugs, it 
is plausible that at least some of the observed alterations in genes involved in 
phospholipid metabolism may have biological and clinical relevance [307,308].  
 
Some of the most studied metabolic pathways in cancer are the glycolytic and fatty 
acid oxidation and biosynthesis pathways [264,276–279,309]. Here, we also explored 
the degree to which genes that are involved in these pathways were altered in each 
of the 32 cancers. In all cancers, we found alterations to some of the genes involved 
in the glycolytic and fatty acid oxidation and biosynthesis pathways (Figure 4-10, 4-
10, 4-11, and 4-12 in the methods section). We found that these gene alterations were 
most frequent in uterine corpus endometrial carcinomas and skin cutaneous 
melanomas. 
 
Finally, we used the literature to identify a subset of genes that encode proteins which 
are either key metabolic enzymes of the central metabolic pathways or are regulators 
of these enzymes. We discovered that 78% of all tumours harbour alteration in these 
genes (Figure 4-4). Among the most frequently altered metabolic regulators were 
PTEN (in 14% of all tumours), KRAS (in 11%) and MYC (in 11%). These gene 
alterations were most frequent in uterine carcinosarcoma (98.2% of patients’ tumours) 
and least frequent in thyroid carcinomas (in 12.4% of tumours; Figure 4-4B).  
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Collectively these results reiterate that alterations within genes involved in particular 
aspects of lipid, carbohydrate and amino acid metabolism are found in many different 
cancers.   
 
4.2.3 Alterations of genes involved in metabolism are associated with 
alterations of mRNA transcript levels  
We next determined whether alterations in genes that are involved in metabolism are 
associated with alterations to the encoded mRNA transcript levels of these genes. We 
first examined whether the HM and LM cancer supertypes displayed distinct mRNA 
signatures for genes involved in metabolic pathways. Among the 2,325 genes involved 
in metabolism, we found that only 1,977 genes had transcript measurements in the 
TCGA. Therefore, focusing only on these 1,977 mRNA transcripts in all patients 
afflicted with the 32 different cancers, we applied t-distributed stochastic 
neighbourhood embedding (t-SNE) to reduce the dimensions of these data and 
visualised the relationships between cancers using scatter plots. We found that 
whereas the HM cancers displayed similar patterns of mRNA expression (i.e. they 
clustered closer to one another in the scatter plots; Figure 4-5A), the LM cancers 
tended to display more diverse mRNA expression patterns (i.e. they did not cluster as 
much in the scatter plots; Figure 4-5B). Specifically, whereas a three-dimensional t-
SNE plot indicated that the HM cancers tended to group in the centre of the gene 
expression space, the LM cancers were scattered around the periphery of this space 
(Figure 4-5C). 
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Figure 4-4: Major catabolic and anabolic pathways of glucose and lipid metabolism in human cells. 
Nodes represent either enzymes (blue outline colour) or metabolic regulators (red outline colour). Node 
colours represent tumour suppressors (blue) and oncogenes (red) and their increasing colour intensities 
denote higher percentages of tumours with alterations in the genes encoding these enzymes or 
regulatory proteins. Edges indicate known types of interaction: red for inhibition and green arrows for 
AlterationsinEachCancerType
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activation.  Abbreviations: GLUTs, all glucose transporters; HK, hexokinase; PFK, 
phosphofructokinase; PK, pyruvate kinase; LDH, lactate dehydrogenase; PDH, pyruvate 
dehydrogenase complex, PDK; pyruvate dehydrogenase kinase; CS, citrate synthase; ACO2, cis-
aconitase; IDH, isocitrate dehydrogenase; OGDH, α-ketoglutarate; SDH, succinate dehydrogenase; 
SUCL, succinyl-CoA lyase; FH, fumarate hydratase; MDH, malate dehydrogenase; ACLY, ATP-
dependent citrate lyase; ACC, acetyl-CoA carboxylase; FASN, fatty acid synthase; PTEN, phosphatase 
and tensin homolog; AMPK, 5'-AMP-activated protein kinase; mTORC1, mechanistic target of 
rapamycin complex-1; PI3K, phosphoinositide-3 kinase; SREBP, Sterol regulatory element-binding 
protein; Akt, RAC-alpha serine/threonine-protein kinase; Kras, Kirsten rat sarcoma viral oncogene 
homolog; Myc, MYC proto-oncogene; HIF1α, hypoxia-inducible factor 1-alpha; LKB1, Liver Kinase B1; 
p53, p53 tumour suppressor. (B) overall fraction of samples with the central metabolic pathways gene 




Figure 4-5: TCGA tumour grouping based on metabolic gene transcript level: (A) Clustering of HM 
(orange points) and LM (blue points) tumours based on mRNA transcript levels. (B) Clustering of 32 
different cancer types based on mRNA transcript levels. Points are coloured according to the type of 
cancer they represent. For both plots (A and B), t-SNE was used to visualise the tumour classes using 
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the exact algorithm and standardised Euclidean distance metric. (C) Three-dimensional plot of the 
HM/LM tumour supertype grouping based on mRNA transcript levels.  (D) The integrated plot of mRNA 
expression correlations ordered by whether cancers belong to the HM or LM supertypes. From top to 
bottom, panels indicate: The tissue of origin; whether tumours belong to the HM or LM supertype; 
heatmap of inter-tumour linear Pearson’s correlation scores with increasing colour intensities denoting 
higher degrees of correlation.  
 
Since the HM cancers tended to cluster together, we hypothesized that their metabolic 
gene expression profiles were highly correlated. To test this hypothesis, we measured 
the Pearson’s linear correlation coefficients between transcript abundances across 
each pair of the 32 human cancers (see methods section). We establish that whereas 
the mRNA transcript levels of the 1,977 metabolic genes of each pair of HM cancers 
tended to be strongly positively correlated (mean Pearson’s correlation = 0.9; range: 
0.79 to 0.98), there tended to be weaker positive correlations between the mRNA 
transcript levels seen between the LM cancers (mean Pearson’s correlation = 0.68; 
range: 0.40 to 0.92; Figure 4-5D). 
 
Overall, these results indicate that while gene expression profiles are relatively 
conserved among the HM cancers, they are more diverse in the LM cancers. 
 
Since the relative uniformity of the HM group was intriguing, we decided to further 
evaluated tumours in this supertype using data on all 20,502 of the mRNA transcripts 
that are available in the TCGA database (i.e., not only the transcript of metabolic 
genes). Here, we applied t-SNE to visualise the grouping of HM tumours (Figure 4-
6A) and also applied Density-based spatial clustering of applications with noise 
(DBSCAN; [310])  approach to classify the tumour into various subgroups(Figure 4-
6B). We found that patients afflicted with the different subgroups of tumours identified 
using DBSCAN exhibited different durations of DFS (Figure 4-6C) and OS (Figure 4-
6D).  
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Figure 4-6: DBSCAN tumour classification (A) Clustering of HM tumours based on all 20,502 mRNA 
transcript levels that were measured by the TCGA project.  The colour legend represents different 
cancer types. (B) Clustering of HM tumours based on all 20,502 mRNA transcript levels that were 
measured by the TCGA. Points are coloured according to the clustering of the tumour using DBSCAN. 
-1 indicates the outlier points. For both plots (A and B), t-SNE was used to visualise the tumour classes 
using the exact algorithm and standardised Euclidean distance metric. (C) Kaplan-Meier curve of the 
disease-free survival periods and the life table of patients afflicted with each DBSCAN disease subtype. 
(D) Kaplan-Meier curve of the overall survival periods and life table of patients afflicted with each 
DBSCAN disease subtype. For both survival curve plots (C and D), the colours represent the tumour 
groupings yielded by DBSCAN in panel B.   
 
4.3.4 The drug responses of cancer cell lines are associated with metabolic 
gene alterations  
From the GDSC database, we collected gene alteration data (including single 
nucleotide mutations, indels and copy number alterations) for 812 cancer cell lines of 
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30 different human cancer types.  Each of these cell lines also has dose-response 
profiles to 251 anticancer drugs (Figure 4-6A) [5]. We assessed the patterns of 
metabolic gene alterations within these cancer cell lines and discovered that these 
were similar to those of the primary tumours (Figure 4-6B).  
 
Given that previous studies have underlined differences in molecular characteristics 
between cancer cell lines and their primary tumour tissues [311,312], we directly 
compared metabolic gene alterations between cell lines and tumours of the same 
type. This revealed that, with only two exceptions, there were no significant 
differences in the frequencies of metabolic gene alterations between the cell lines 
and primary tumours of a given cancer type. The two exceptional cases were acute 
myeloid leukaemia (chi-square = 22.7, p = 1.9 x 10-6) and thyroid carcinoma (chi-
square = 16.7, p = 5 x 10-4) for which the cell lines have significantly higher 
frequencies of metabolic gene alterations than did primary tumours (Figure 4-6B; 
supplementary file 1). 
 
 
Figure 4-7: GDSC cell lines and the mutational and dose-response characteristics: (A) Distribution of 
1,001 cancer cell lines derived from 32 human cancer types broken down by tissue of origin. (B) 
Heatmap of the fraction of altered GDSC cancer cell line genes that are involved in each first-tier 
metabolic pathway in relation to corresponding patient tumour data from TCGA. Pathways are ordered 
according to numbers of observed alterations within genes that are involved in the pathways. Increasing 
colour intensities denote higher percentages of tumours containing alterations in the genes involved in 
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alterations within GDSC cell lines (blue bars) or TCGA tumours (tan bars) of a particular cancer type. 
Bar graphs on the right of the heatmap indicate the overall percentage of alterations within each first-
tier metabolic pathway for the GDSC cell lines (blue bars and TCGA tumours (tan bars). (C) The number 
of anticancer drugs that target 24 signalling pathways and/or biological process that were used by the 
GDSC to treat cancer cell lines. Colours indicate the targeted pathways. (D) Comparison of the dose-
response profiles between the LM and HM supertypes of the GDSC cancer cell lines. Bar graphs 
indicate logarithm transformed mean IC50 values of the cancer cell lines that correspond to the HM 
(orange bars) and LM (blue bar) cancer supertypes. The error bars indicate the standard error of the 
mean logarithm transformed IC50 value for each class of anticancer drug. The start indicates the levels 
of statistical significance; three stars for p values less than 0.001, two stars for p values less than 0.01 
and one star for p values less than 0.05. 
 
Next, we classified the cancer cell lines into either the HM or LM supertypes using the 
TCGA cancer type labels of each cell line that are provided within the GDSC database. 
We then compared drug IC50 values between HM and LM cell lines for 24 classes of 
drugs that target 24 signalling pathways and/or biological processes (Figure 4-7C). 
Remarkedly, we uncovered differences between the HM and LM cancer cell lines in 
their observed dose-responses to various classes of anticancer drugs. Compared to 
the HM cell lines, the LM cell lines were significantly more sensitive to seven out of 
the 24 classes of anticancer drugs (Figure 4-7D; supplementary file 2). The drugs to 
which the LM cell lines were significantly more sensitive than the HM cell lines were 
those targeting pathways and biological processes such as receptor tyrosine kinase 
signalling, cytoskeleton structure, genome integrity processes, Wnt signalling, the cell 
cycle, PI3K/mTOR signalling, DNA replication, and kinases that are involved in 
multiple signalling pathways. Surprisingly, the HM cell lines were only significantly 
more sensitive than the LM cell lines to drugs that target the EGFR signalling pathway 
(Figure 4-7D; supplementary file 2). 
 
We next compared the IC50 values of all 251 individual drugs with which the LM and 
HM cell lines were treated, regardless of the drugs’ modes of action. Here, we found 
that, after correcting for multiple comparisons, the IC50 values of 41 anticancer drugs 
differed significantly between the LM and HM cell lines (supplementary file 2). 
Interestingly, the HM cell lines were more sensitive to only five of these 41 drugs. 
These included afatinib (p = 2.1 x 10-9), CP724714 (p = 5.5. x 10-4), gefitinib (p = 6.3 
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x 10-4), TAK-715 (p = 0.02), and vinorelbine (p = 0.049). Among these, afatinib, 
CP724714 and gefitinib target the EGFR signalling pathway, whereas TAK-715 
targets JNK and p38 signalling, and vinorelbine inhibits mitosis by destabilising 
microtubules (Figure 4-7D and supplementary file 2). Conversely, we observed that 
the LM cell lines were significantly more sensitive than the HM cell lines to 36 of the 
anticancer drugs including CHIR-99021(p = 4.6 x 10-7), QL-XI-92 (p = 4.6 x 10-7) and 
SN-38 (p = 9.2 x 10-5; see supplementary file 2). 
 
Overall this indicates that frequencies of metabolic gene alterations (our exclusive 
criterion for placing cell lines into the LM and HM supertypes) is a highly relevant 
variable when attempting to predict the drug responsiveness of cell lines and, 
therefore, that it may also be a clinically relevant variable when predicting the drug 
responsiveness of primary tumours.    
  
4.3.5 The subtypes within each cancer exhibit diverse responses to anticancer 
drugs 
For each of the 32 TCGA cancer types, we applied unsupervised hierarchical 
clustering to counts of alterations within genes involved in the 16 first-tier metabolic 
pathways to identify disease subtypes within each cancer type (see examples in 
Figure 4-15). Here, we found that (aside from genes involved in lipid, carbohydrate, 
and amino acid metabolism) subgroups of patients are likely to harbour additional 
alterations in other metabolic pathways. For example, in the case of glioblastoma 
multiforme (Figure 4-15A) and lung adenocarcinoma (Figure 4-15B), we found that 
while almost all the tumours represented in TCGA have alterations to genes involved 
in lipid, carbohydrate and amino acid metabolism pathways, small groups of tumours 
usually show even higher numbers of alterations to genes involved in, amongst others, 
the abacavir and nitric oxide metabolism pathways. 
 
Since the frequencies of alterations to genes involved in metabolic pathways are likely 
to influence the responses of patients to anticancer drugs, we identified GDSC cancer 
cell lines displaying similar gene alterations to those found in individual primary 
tumours to test whether this might be the case (see methods section). Here, we 
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applied an approach were, for all cell lines of a particular human cancer, we compared 
their IC50 values for each of the 251 anticancer drugs between the cell lines with or 
without alterations to genes involved in each of the 16 first-tier metabolic pathways. 
Interestingly, we found that for cell lines of a particular cancer type, there are gene-
alteration-dependent differences in their dose-responses to various anticancer drugs 
(supplementary file 2). For example, 51 anticancer drugs demonstrated significantly 
higher efficacies on oesophageal adenocarcinoma cell lines that have alterations in 
genes involved in abacavir metabolism pathways than on oesophageal 
adenocarcinoma cell lines without alterations to these genes (Figure 4-8A). Also, cell 
lines of lung adenocarcinoma with alterations in genes involved in the biological 
oxidation pathways are significantly more resistant to 52 anticancer drugs than are 
those without alterations to these genes (Figure 4-8A).  
 
Altogether, we found 2,186 instances where alterations to genes involved in a specific 
metabolic pathway are associated with the efficacy in the cancer cell lines 
(supplementary file 2). Among the metabolic pathways, we found that those of 
cytoplasmic iron-sulphur clusters (447 instances), nucleotide metabolism (292 
instances), and amino acid and derivatives metabolism (293 instances; Figure 4-8A) 
were associated with varied efficacies of the highest numbers of anticancer drugs for 
all the cancer cell lines across all tumour types.  
 
Given that we had found that tumours displaying different numbers of alterations to 
metabolic genes exhibit different clinical and survival outcomes, we decided to 
examine this in more detail for particular cancer types. Using data of primary cancers 
from the TCGA, for patients’ tumours with or without alterations in genes involved in 
abacavir metabolism, we found that the durations of the disease-free progression 
periods were significantly lower for oesophageal adenocarcinoma patients with 
alterations to these genes (log rank p = 0.004; Figure 4-8C).  Conversely, disease-
free progression periods were higher for uterine corpus endometrial carcinoma 
patients with alterations to genes involved in abacavir metabolism (log rank p = 0.041; 
Figure 4-8D). This then indicates that, even within each cancer type, the numbers of 
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alterations found in metabolic genes involved in particular pathways can, in addition 
to influencing anticancer drug responses, detectably impact patient survival.  
 
 
Figure 4-8: Metabolic pathway gene alteration-dependent dose-responses and disease outcomes: (A) 
Dose-response profiles for drugs that have a degree of efficacy that is influenced by alterations in genes 
involved in specific metabolic pathways. From left to right: the columns represent GDSC cancer cell 
lines of various cancer types. The sizes of squares represent the number of drugs with efficacies that 
differ significantly between cell lines with and without gene alterations in the pathways indicated along 
the rows.  The marks are coloured based on the overall influence of the metabolic gene alterations on 
drug efficacy: with increasing blue intensities denoting increasing sensitivity and increasing orange 
intensity denoting increasing resistance. The heatmap represents the overall numbers of drugs whose 
efficacy is influenced by the altered metabolic genes that are involved in the represented pathways. 
The bar graphs represent the total numbers of drugs whose dose-responses are increased (blue) or 
decreased (orange) by alterations of genes that are involved in the respective pathways. (B) Kaplan-
Meier curve of the disease-free survival periods of patients afflicted with oesophageal adenocarcinoma 
with or without alterations to genes involved in the abacavir metabolism pathway. (C) Kaplan-Meier 
curve of the disease-free survival periods of patients afflicted with uterine corpus endometrial 
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4.3 Discussion 
Metabolism is an essential process within all living cells. Thus, we examined the 
relationships between the numbers of alterations within the metabolic genes of primary 
tumours and cell lines of 32 different human cancer types and both clinical outcomes 
and likely drug responses. Others have used mRNA transcript data to show that 
alterations in metabolic pathways likely differ substantially between human cancer 
types [269,270]. To the best of our knowledge, ours is the first study to characterise 
metabolic gene alterations across such a large number of primary tumours (10,528) 
for so many distinct cancer types (32).  
 
While we found at least one altered metabolic gene in every one of the 10,528 
analysed tumours, the numbers of altered metabolic genes varied between the 32 
cancer types that these tumours belonged to. We demonstrated that a clinically 
relevant clustering of patient tumours, irrespective of the type of cancer they 
represented, could be achieved by simply dividing the tumours into two supertypes 
based entirely on the numbers of alterations they displayed in metabolic genes: an LM 
supertype for low numbers of metabolic gene alterations and an HM supertype for high 
numbers of metabolic gene alterations (Figure 4-1B). Just as others have shown that 
alterations of genes involved in signalling pathways can have clinical implications 
[85,313], we show here that individuals with HM tumours tend to have significantly 
worse clinical outcomes than those afflicted with LM tumours. As such, our results 
suggest that simple counts of metabolic gene alterations in a tumour can provide a 
quantitative approximation of the extent of metabolic dysregulation within the tumour 
and, hence, an indirect approximation of the aggressiveness of the tumour.  
 
Our analyses indicate that alterations of genes involved in the central metabolic 
pathways and the regulators of these pathways are pervasive across all human 
cancers (Figure 4-4). Among the most commonly altered of the regulatory genes that 
are involved in cellular metabolism were PIK3CA (in 32% of tumours), MYC (in 14%) 
and HIF1A (in 11%). In various cancers, MYC and HIF1A alterations dysregulate 
multiple metabolic enzymes including, hexokinase, isocitrate dehydrogenase, 
pyruvate dehydrogenase kinase and lactate dehydrogenase [314,315]. Further, 
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PIK3CA, MYC, HIF1A and other genes with frequent alterations in primary tumours 
are known to dysregulate cellular metabolism by increasing the rate of glycolysis while 
reducing the rate of aerobic respiration; a phenomenon referred to as the Warburg 
effect [265,314,316]. Tumours that exhibit a Warburg phenotype are known to be more 
aggressive and respond more poorly to most anticancer drugs [317]. Accordingly, 
compared to the LM cancers, we found higher alteration rates of the Warburg 
phenotype-associated genes in the HM cancers, which could explain why patients 
afflicted with HM cancers tend to have worse survival outcomes.   
 
Changes in various signalling pathways are associated with variations in the response 
of cancer cells to drug perturbations, and these changes can, therefore, impact 
disease treatment outcomes [222,223]. Prior to the provision of anticancer drugs, it is 
desirable to know the drugs to which a particular tumour is most likely to be 
responsive. Since it is practically impossible to test hundreds of individual drugs on a 
specific tumour, cell lines that have phenotypic features resembling that of the tumour 
may be useful in predicting the drug responses of that tumour [5,7,73,227]. 
Accordingly, using drug response data for cancer cell lines, we inferred that HM and 
LM cancers are likely to respond differently to various anticancer drugs. Specifically, 
HM cancers tended to be less responsive to most anticancer drugs than LM cancers. 
This suggests that in addition to HM tumours potentially being more aggressive than 
LM tumours, patients afflicted with HM cancers may also exhibit worse clinical 
outcomes simply because HM cancers are more refractory to most anticancer drugs 
(supplementary file 2). Also, since our results indicate that HM tumours are likely to 
only respond to higher doses of anticancer drugs, it would follow that patients with 
such tumours would tend to experience more adverse drug effects and treatment-
associated complications, both of which could unfavourably impact their survival [318–
321].  
 
Drugs such as afatinib and gefitinib, which target the EGFR signalling pathway were, 
however, found to have significantly higher efficacies in HM cell lines than in LM cell 
lines. Currently, afatinib is the first-line treatment for patients with metastatic non-small 
cell lung cancer, and it has also been evaluated for the treatment of head and neck 
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squamous cell carcinoma [322,323]. In our analyses, both non-small cell lung cancer 
and head and neck squamous cell carcinoma are HM cancers, and we predict, 
therefore, that there is a strong likelihood that many other HM cancers such as skin 
cutaneous melanoma, bladder urothelial carcinoma and lung adenocarcinoma may 
also respond to drugs that target the EGFR signalling pathway.  
 
It is important to emphasise that our LM/HM classification is very simplistic. Taking a 
step back, we are reminded that among tumours that are derived from any particular 
tissue, there exist distinct tumour subtypes that differ from one another both in the 
gene alterations they display, and in the actual metabolic perturbations that these gene 
alterations cause [86,89,96,188,269]. In many respects, these distinct tumour 
subtypes are different diseases requiring different treatments [7,85,227].  
 
We noted differences in the efficacy of various anticancer drugs between cell lines of 
the same primary cancer type. In some cases, these differences were associated with 
the presence or absence of alterations to genes involved in a particular metabolic 
pathway. This is in concordance with several recent studies that have established links 
between gene alterations and drug action [5,73,85,187,324,325]. This then supports 
the assertion that for any given cancer patient, the overall landscape of metabolic gene 
alterations could be used to identify generally applicable anticancer drug classes, 
following which alterations to specific metabolic genes could be used to eliminate the 
remaining drug choices that have the highest chances of failure.  
 
Our results have shown that within each of the 32 cancer types, there exist subtypes 
that have alterations in genes that are involved in metabolic pathways that are less 
commonly associated with cancers (Figure 4-15). Interestingly, we found that for 
different cancer types, alterations of genes involved in a particular metabolic pathway 
may not produce similar clinical outcomes. For example, we found that for patients 
with alterations to genes involved in abacavir metabolism, those afflicted with 
oesophageal adenocarcinoma present with worse outcomes whereas those afflicted 
with uterine corpora endometrial carcinoma present with better outcomes (Figure 4-
8B and Figure 4-8C).  Such a scenario has been shown in other cancers. For instance, 
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activation of the mitogen-activated kinase pathway is associated with worse clinical 
outcomes in ovarian and colorectal cancer [326,327], but with better clinical outcomes 
in hormone receptor-negative breast cancer and astrocytoma [328,329].    
 
Altogether, we have shown both that metabolic gene alterations which potentially 
dysregulate metabolic pathways are a pervasive phenomenon across all 32 of the 
investigated human cancer types, and that numbers of metabolic gene alterations are 
linked to treatment outcomes. Further, our analysis of the drug response profiles of 
well-characterised cancer cell lines suggests that alterations of genes of various 
metabolic pathways may also be predictive of drug responses. While we cannot 
guarantee that simply scoring gene alterations of particular metabolic pathways in 
patient tumours will reveal the best available treatment choices for these patients, it is 
apparent that such scores could nevertheless be leveraged to increase the probability 
of making a good treatment choice.  
4.4 Methods 
We analysed a TCGA project dataset of 10,528 patient-derived tumours representing 
32 distinct human cancers (see Figure 4-1A) [96], obtained from cBioPortal [50] 
version 2.20 (http://www.cbioportal.org). The elements of the data that we used to 
identify gene alterations were gene copy number counts and somatic mutations (point 
mutations and small insertions/deletions). We also used mRNA expression data and 
comprehensive deidentified clinical data for all patients.  
 
4.4.1 Metabolic gene alterations in the TCGA cancers  
We accessed information of all human metabolic pathways from the Reactome 
pathways database version 68 [10]. Reactome pathways are arranged into several 
tiers with the Reactome term “metabolism” (Reactome ID: R-HSA-1430728), 
encompassing 68 different metabolic pathways (see 
https://reactome.org/PathwayBrowser/#/R-HSA-1430728). The first-tier pathways 
include sixteen curated metabolic pathways which involve 2,325 genes.  
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For each of the 32 human cancers, we calculated the overall percentage of samples 
with mutations and/or copy number alterations in these 2,325 genes. This provided us 
with alteration frequencies for each metabolic pathway in each human cancer (Figure 
4-1C). We applied unsupervised hierarchical clustering with the squared Euclidean 
distance metric to these data to identify “altered metabolic gene” supertypes of human 
cancers (Figure 4-9). Based on the clustering dendrogram that that this yielded, we 
identified two cancer supertypes, which for simplicity, we named as either HM or LM, 
for those that respectively displayed higher or lower numbers of first-tier metabolic 
pathway associated gene alterations. The clustering of tumours into  the two 
supertypes was highly coherent, with a cophenetic correlation coefficient of 0.89 and 
a Spearman's rank correlation between the dissimilarities and the cophenetic 
distances of 0.9 [310]. 
 
 
Figure 4-9: Unsupervised hierarchical clustergram of tumours assigned to the two metabolic 
supertypes of human cancers. The fractions of tumours with altered genes that are involved in each of 
the 16 first-tier metabolic pathways were used for clustering. The clustergram was produced using the 
Spearman correlation distance metric with complete linkage. 
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We extracted information relating to the genes that encode proteins of the second-tier 
metabolic pathways for only three of the first-tier pathways: those of carbohydrate, 
lipid and amino acid metabolism. Again, we used the approach for determining the 
extent of gene alterations (as described above) to calculate the fraction of tumours 
with alterations to genes involved in second-tier metabolic pathways across each 
cancer type (Figure 4-3). Also, using the same approach, we calculated the fraction of 
tumours with alterations in the genes that encode enzymes of the central metabolic 
pathway and their regulators (Figure 4-4). Further, we calculate the fraction of tumour 
with alterations in genes involved in the glycolytic, gluconeogenesis, fatty acid 
oxidation and biosynthesis pathways (Figure 4-10, 4-10, 4-11, and 4-12). 
 
 
Figure 4-10: Highlight table showing the fractions of tumours with alterations in glycolytic pathway 
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Figure 4-11: Highlight table showing the fractions of tumours with alterations in gluconeogenic pathway 




Figure 4-12: Highlight table showing the fractions of tumours with alterations in mitochondrial fatty acid 
oxidation pathway genes across all human cancers. Increasing colour intensities denote higher 
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Figure 4-13: Highlight table showing the fractions of tumours with alterations in lipid biosynthesis 
pathway genes across all human cancers. Increasing colour intensities denote higher percentages of 
altered genes.  
 
4.4.2 Analysis of mRNA expression profiles of metabolic pathway genes 
across cancers 
We collected mRNA expression data of the genes that were profiled by the TCGA. 
Among this mRNA transcript data, we found information on only 1,977 genes out of 
the 2,325 genes that are involved in metabolism. We used the t-Distributed stochastic 
neighbourhood embedding algorithm to minimise the divergence between the 1,977-
mRNA transcripts across cancers to return a two- and three-dimensional embedding 
of the 32 human cancers [330]. The overall structure of these transcript embeddings 
was visualised using scatter plots, first based on the cancers’ metabolic supertypes 
(HM and LM) and second based on the cancer types (Figure 4-5A, Figure 4-5B, Figure 
4-5C). To test for correlations between the mRNA transcripts of human cancers, we 
first calculated the mean transcript levels of the 1,977 metabolic pathway genes for 
each cancer and then used these mean values to calculate pairwise Pearson’s linear 
correlation coefficients between each pair of the 32 human cancers (Figure 4-5D) 
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We retrieved all 20,502 of the mRNA transcripts that were measured by the TCGA 
project across all cancer studies and applied t-SNE to visualise the clustering of HM 
tumours across a dimensional space (Figure 4-8A). Further, we applied DBSCAN 
[310] to cluster tumours belonging to the HM cancer supertype into various subgroups 
(Figure 4-8A). 
 
4.4.3 Alterations of metabolic genes in cancer cell lines 
We obtained mutation and copy number alteration data for 1,002 cancer cell lines and 
224,202 dose-response profiles of these cell lines to 267 anticancer drugs from the 
Genomics of Drug Sensitivity in Cancer (GDSC) database version 7.0 
(www.cancerRxgene.org) [5]. For downstream analyses, we focused on only the 812 
cancer cell lines for which a complete set of gene alterations and drug response data 
was available.  
 
Next, we calculated the frequencies of alterations in genes involved in the sixteen first-
tier metabolic pathways in the cancer cell lines using the approach previously 
described for the 32 human cancers (Figure 4-6B, Figure 4-14). Finally, we used chi-
square tests to identify possible differences between the TCGA cancers and the 
GDSC cell lines concerning the alteration counts of genes involved in the first-tier 
metabolic pathways (see results in supplementary file 1). 
 
 
Figure 4-14: Heatmap of GDSC cancer lines showing the percentages of cell lines with alterations to 
genes involved in each of the 16 first-tier metabolic pathways. Pathways are ordered by decreasing 
frequencies of gene alterations. Increasing colour intensities denote higher percentages of cell lines 
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4.4.4 Dose-response characteristics of the LM and HM cancer cell lines 
From the list of 812 GDSC cancer cell lines, we returned only 653 cancer cell lines for 
which the GDSC have assigned a TCGA classification to the cell lines’ primary cancer. 
Altogether, these 653 cell lines corresponded to only 23 of the 32 different human 
cancers profiled by the TCGA (Figure 4-6A). The GDSC treated these 653 cancer cell 
lines with 251 distinct anticancer drugs that target 24 different signalling pathways and 
biological processes (Figure 4-6C). 
   
We used Student t-tests to compare the mean differences in the logarithm transformed 
IC50 values between the HM and LM cell lines for each class of anticancer drugs that 
we segregated based on the target signalling pathway and/or biological process 
(Figure 6D, also see supplementary file 2). Additionally, we compared the mean 
differences in the logarithm transformed IC50 values between HM and LM cell lines 
for each anticancer drug separately (supplementary file 2).  
 
4.4.5 Identification of metabolic disease subtypes for each cancer type 
For each of the 32 human cancer types, we calculated the frequency of alterations to 
genes involved in the 16 first-tier metabolic pathways. We then applied unsupervised 
hierarchical clustering to these data to identify subtypes of disease for each cancer 
(see examples in Figure 4-15). 
 
4.4.6 Comparison of dose-response profiles within each cancer type for 
tumours with or without specific pathway alterations 
For each particular human cancer, we collected all corresponding cell lines from the 
GDSC database. Then, for each of the 16 first-tier metabolic pathways, we segregated 
these cancer cell lines into two groups: those with and those without alterations in 
genes involved in a particular metabolic pathway. Finally, we compared the logarithm 
transformed IC50 values for each of the 251 anticancer drugs between the two groups 
of cell lines using the Wilcoxon rank sum test. Subsequently, we only returned drugs 
that had associated IC50 values which differed significantly between cell lines of 
human cancers with and without alterations of genes involved in a particular metabolic 
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pathway (Figure S8 and supplementary file 2). Note that these comparisons were only 
made in the cases were at least four cell lines had alterations of genes involved in a 
particular metabolic pathway and at least four other cell lines did not have such 
alterations.   
 
 
Figure 4-15: Metabolic pathway gene alterations within cancer types. The clustergrams of gene 
alterations in various human cancer types. Only nine examples of cancer types are shown. The 
clustergrams show the percentage of tumours with alterations to genes involved in each of the 16 first-
tier metabolic pathways. 
 
4.4.7 Survival analysis  
The Kaplan-Meier method was used to estimate overall survival and the duration of 
progression-free survival between the HM and the LM supertypes of human cancer 
[160]. To validate our findings concerning the overall survival of the TCGA HM and LM 
supertypes, we downloaded an independent dataset of overall survival outcomes from 
the  ICGC data portal [9] for individuals afflicted with tumours of types corresponding 
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datasets from the TCGA, we removed these to return a dataset of 3,146 patient 
tumours that are unique to the ICGC. Next, we classified these the ICGC patient 
tumours into the HM or LM supertype categories based on the TCGA classification 
label provided within the ICGC database. We then compared the overall survival of 
these HM and LM patients. Also, the Kaplan-Meier method was applied to assess the 
survival outcomes of oesophageal adenocarcinoma and uterine corpus endometrial 
carcinoma patients who had tumours with or without alterations to genes involved in 
the abacavir metabolism pathway. The Kaplan-Meier method was also used to 
estimate OS and DFS between the subgroups of HM tumours that we identified using 
DBSCAN. 
 
4.4.8 Statistical analyses  
All statistical analyses were performed in MATLAB 2019a. Fisher's exact test was 
used to assess associations between categorical variables.  The independent sample 
Student t-test or the Wilcoxon rank sum test and the one-way Analysis of Variance 
were used to compare continuous variables where appropriate. Statistical tests were 
considered significant at p < 0.05 for single comparisons, whereas the p-values of 
multiple comparisons were adjusted using the Benjamini-Hochberg method.  
4.5 Ethics Approval  
The University of Cape Town; Health Sciences Research Ethics Committee 
IRB00001938 approved the protocol of this study. This study involved the analysis of 
publicly available datasets that were collected by the TCGA, ICGC, GDSC and other 
databases from consenting participants. All methods were performed following the 
relevant policies, regulations and guidelines provided by the TCGA, ICGC, GDSC and 
other databases for analysing their datasets and reporting of the findings. 
4.6 Supplementary Information   
Supplemental Information can be found online at 
https://zenodo.org/record/3253843#.XRCj7C2B2u4. The supplementary file 
descriptions are provided in appendix A.   
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Chapter 5 : General Conclusion   
5.1 General Discussion  
 
I have highlighted how, in the post-genomics era, we can integrate big data from 
various resources to decipher the molecular characteristics of human diseases. Using 
large-scale datasets produced by high-throughput technologies such as next-
generation nucleotide sequencing and protein mass spectrometry, my PhD project has 
exemplified how it is possible to move away from only studying the role(s) in a given 
disease of one or a few genes and/or proteins, to simultaneously studying the roles 
of, and relationships between, almost all the genes and proteins that might impact that 
disease [332,333].  In the current study, by applying an integrative “data-first” 
approach, I have shown that we can establish a multiscale appreciation of the cellular 
regulatory mechanisms that are at play in different forms of pancreatic cancer. For 
example, I showed that MAPK-PI3K-mTOR signalling pathways primarily drive the 
QM-PDAC disease subtype, whereas the p53 and cell cycle checkpoint pathways 
primarily drive the EL-PDAC subtypes (Figure 2-7 and 2-10). Also, I revealed that 
these subtypes of pancreatic cancer could likely be treated by targeting hub kinases 
within the dysregulated signalling pathways that are unique to each disease subtype 
(Figure 2-13). 
 
To arrive at these findings, I integrated genome-wide expression data with prior 
biological knowledge extracted from the KEGG pathways, Reactome Pathway, ChEA, 
KEA, GO, and UCSC super-pathways databases. The use of such prior knowledge 
from multiple sources to construct metabolic and signal transduction networks of 
protein-protein interactions has drastically improved our predictive understanding of 
cellular systems [1,332,334,335].  However, just as prior knowledge has helped inform 
my network-based analyses, the remaining gaps in our current knowledge of the 
human interactome  [332,333,336–340] have also constrained the precision of the 
inferences that I could draw from my analyses. To achieve maximum power with the 
types of analyses carried out in this thesis, there is, therefore, a pressing need to 
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improve the coverage of information on the various pathway databases to include all 
of the interactions between all human genes and all human proteins. Only with a 
complete comprehension of how cellular regulatory networks coordinate the 
underlying behaviours of complex biological systems can we fully comprehend how 
perturbations of these systems result in disease. 
 
To put our current knowledge of cellular proteins into context; despite advances in 
bioinformatics and systems biology, we only understand the functions of ~65% of all 
the known human proteins.  Further, only 3% of all the cellular proteins are presently 
targeted by drugs in clinical settings (Figure 6-1). We urgently need to identify the 
functions and interaction partners of the 35% of human proteins that we know virtually 
nothing about; only then can we develop more detailed network models that could then 
be used to more effectively mine transcriptomics, proteomics and other publicly 




Figure 5-1: Our current knowledge of human proteins. Tdark; these are human proteins about which 
virtually nothing is known. They do not have known interactions with either any known drugs or other 
small molecules. Tbio; these proteins also do not have interactions with either any known drugs or other 
small molecules, but are both annotated with a gene ontology molecular function or biological process 
term(s) derived from experimental evidence, and have known phenotype annotations. Tchem; these 
are proteins with known functions that interact strongly with at least one ChEMBL compound (with an 
activity cutoff of < 30 nM) that does not have an approved application in clinical settings. Tclin; these 
are proteins with known functions that interact with at least one approved drug (i.e. a ChEMBL 
compound with approved application(s) in a clinical setting). We retrieved information of these targets 
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from Pharos (https://pharos.nih.gov/targets/); an integrated knowledgebase for illuminating the 
druggable genome [129]. 
 
Despite these challenges, I have shown that numerous opportunities still exist to 
leverage multiple high-throughput data sources to define the clinical relevance of 
disease subtypes. For instance, I showed that the mutational profiles of most cancer 
cell lines are similar to those of the primary tumours from which the cell lines 
originated. Also, I showed that patients’ tumours of various cancers could be 
compared to their corresponding cell lines to understand how genetic changes within 
cancer cells that impact metabolic pathways affect the responses of tumour cells to 
hundreds of anticancer drugs. 
 
The backdrop to these results are studies which, to the contrary, have suggested that 
such comparisons are misleading because cancer cell lines are generally genetically 
not similar enough to the primary tumours from which they were derived [311,312]. 
Further, others have suggested that the comparison of genomic features and cell line 
drug response profiles from databases such as the GDSC may yield inconsistent 
associations [341]. Some of the observed inconsistencies are likely attributable to the 
diverse molecular profiling platforms and different computational analysis pipelines 
that have been employed in different studies [342–345]. Therefore, in this big-data 
era, it is essential to continually benchmark and standardise molecular datasets 
between and across experiments, so that various datasets obtained using different 
platforms are easily comparable [346–348]. In all such instances, knowledge of the 
underlying biology should guide the implementation of the data mining, machine 
learning and network modelling techniques that are applied to extract meaningful 
insights from such data. As such, our ability to integratively analyse large-scale 
datasets that have been obtained from multiple publicly available resources, and 
interpret the computational outputs of these analyses to identify the molecular 
predictors of drug dependencies, remains a pivotal challenge of precision cancer 
medicine. 
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In chapter three, I established that pancreatic cancer tumours clustered differently 
depending on the specific molecular data types that are examined (DNA methylation 
status, protein expression levels and mRNA/ miRNA transcription levels; Figure 3-1A). 
To mitigate this problem, I applied SNF, a multi-platform integrative clustering method 
that, in this case, took into consideration the full spectrum of available molecular data 
to define the two main subtypes of pancreatic cancer. Further, I integrated known 
protein-protein interactions with either mRNA transcription data or proteomics data to 
identify signalling pathways that are altered in these two pancreatic cancer subtypes. 
Here, I uncovered little overlap in the enriched signalling pathways identified when 
focusing either on upregulated mRNA transcripts or on upregulated proteins that I 
observed in only one of the two pancreatic cancer subtypes (Figure 3-5B and 3-3A).  
 
Importantly, these results showed that besides issues related to the heterogeneous 
nature of the available molecular datasets, we are also still challenged by the 
fundamental complexity of biological regulatory networks. One of the consequences 
of this is the disparate clustering of the same sets of patients based on different 
sources of molecular data. This problem has been observed in studies of many other 
human cancers, including acute myeloid leukaemia, adrenocortical carcinoma, 
muscle-invasive bladder carcinoma, breast cancer, cervical cancer, 
cholangiocarcinoma, colorectal cancer, oesophageal carcinoma, glioblastoma, 
hepatocellular carcinoma, papillary renal cell carcinoma, malignant pleural 
mesothelioma, and prostate cancer [349–359].  
 
Given the growing availability and size of big datasets, we advocate an approach 
where different types of molecular datasets that are all gathered for the same sets of 
patients are accurately integrated to identify unified disease subtypes. Ideally, we 
need to reach a consensus regarding the unified molecular disease subtypes of each 
human cancer; this would allow for the consistent identification of the causal molecular 
process disruptors that underlie each disease subtype. Once such subtypes are 
defined for a particular cancer, the clinical utility of such a classification scheme will 
depend on both the practical viability of assaying tumours for subtype-specific 
biomarkers, and the reliability with which these biomarkers can be used to assign 
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tumours to these subtypes. Altogether, my results demonstrate that, when one takes 
a multidimensional view of cellular regulatory systems using different molecular 
datasets, it is possible to identify small numbers of prospective biomarkers that can 
be used to reliably classify complex diseases such as cancer. 
 
I have shown that alterations to metabolic genes which potentially dysregulate 
metabolic pathways are a pervasive phenomenon across 32 forms of human cancer. 
Interestingly, alterations to genes involved in specific metabolic pathways may be 
associated with contrasting disease outcomes. For example, using data from the 
TCGA for patients' tumours with or without alterations in genes involved in abacavir 
metabolism, we found that the duration of DFS periods was significantly lower for 
oesophageal adenocarcinoma patients with alterations to these genes (log-rank p = 
0.004; Figure 4-8C).  Conversely, DFS periods were higher for uterine corpus 
endometrial carcinoma patients with alterations to genes involved in abacavir 
metabolism (log-rank p = 0.041; Figure 4-8D).  
 
Further, we found that alterations to genes involved in specific metabolic pathways are 
associated with the dose-response of cancer cell lines to anticancer drugs. 
Paradoxically, we find that in some cases, these associations differ between different 
cancers. For example, 126 anticancer drugs demonstrated significantly higher 
efficacies on glioblastoma multiforme cell lines that have alterations in genes involved 
in amino acid metabolism pathways than on glioblastoma multiforme cell lines without 
alterations to these genes (Figure 4-8A). Conversely, 67 anticancer drugs 
demonstrated significantly lower efficacies on kidney renal clear cell carcinoma cell 
lines that have alterations in genes involved in amino acid metabolism pathways than 
on kidney renal clear cell carcinoma cell lines without alterations to these genes 
(Figure 4-8A). These results illustrate the complexity of biological systems at the tissue 
level, i.e., genetic alterations have a tissue-specific context [360] which determines 
how they affect certain tumour characteristics: including the response of tumours to 
anticancer drugs and the aggressiveness of the disease.   
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Alterations to a particular gene may have different impacts on the physiology of 
different tissues because the gene may carry out different functions in different cell 
types and tissues [360–362]. For example, whereas in some cell lines, p53 levels 
oscillate with fixed periodicity in response to cellular perturbations, in other cell lines 
p53 levels change dynamically by either a single broad pulse or by continuous 
induction [363]. Likewise, DUSP4, which is a well-known negative regulator of ERK 
activity in various tissues, unexpectedly promotes ERK activity in various cancers, 
including that of the lung [364,365]. DUSP4 and other DUSP family proteins are thus 
considered a double-edged sword in cancer progression as they may act as 
oncogenes or tumour suppressor genes depending on the tissue or cancer type 
[364,366]. Likewise, we have recently showed that the mutations in MAPK pathway 
genes may be associated with mixed responses of the cell lines to the MAPK pathway 
inhibitors, i.e., some cells lines with these mutations tend to display more robust 
responses to MAPK inhibitors than others [367].   
 
The fact that many other signalling pathways are likely to exhibit similarly variable 
biological impacts to those I observed during my analysis of metabolic pathways 
highlights the limitations of the current signalling pathway models and other prior-
knowledge network models that are widely applied in systems biology research. These 
models are generally not cell-type or tissue-specific but are instead curated based on 
our understanding of whole-body cellular physiology. Making universal analytical 
assumptions about cell signalling based on these models may yield difficult to interpret 
results and/or biologically implausible conclusions [363]. Currently, this is a 
challenging unsolved problem that must be directly confronted when deciphering the 
causes and biological consequences of signalling pathway or network alterations. 
Altogether, I have concluded that there is a critical need to define regulatory network 
connections individually for all of the different cell types and tissues so as to enable 
the formulation of accurate cell-type and tissue-specific network models. 
 
In this regard, the library of integrated cellular-based signatures (LINCS, 
http://www.lincsproject.org) has recently embarked on a multi-centre project to 
address some of the challenges of using the data integration techniques that I have 
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presented in this thesis to more fully understand complex cellular systems [3,29]. The 
overall goal of this project is to determine the molecular and functional changes that 
occur in thousands of different human cell types following drug exposure and/or 
genetic perturbations. For example, the Harvard Medical School LINCS Center is 
"addressing a range of technical and conceptual challenges related to collecting and 
analysing feature-rich data on cellular pathways and mechanisms of drug action" 
(https://lincs.hms.harvard.edu). The LINCS datasets offer fresh prospects to the 
broader scientific community to link biochemical and imaging data on cell signalling 
pathways (measured using protein levels, protein activities, receptor activation, kinase 
modification and transcription factor activation) to gene expression and other 
perturbations caused by the exposure of cells to small-molecules, drugs and 
cytokines. By integrating the LINCS datasets, and linking these data with other big 
data resources, we will be able to construct complex curated regulatory networks that 
are cell-type and context-specific. Besides providing completely novel biological 
insights, such a multiscale systems-level view of different cellular states in various 
contexts will both help us gain a more detailed understanding of known signalling 
pathways, and support efforts to develop therapies aimed at restoring perturbed 
pathways and networks to their normal states. 
Altogether, in this thesis, I have focused on showing the practical utility of leveraging 
data-first approaches, machine learning, and network analyses to achieve novel, 
potentially actionable insights into the pathophysiology of cancers.  Besides showing 
the ways in which big data resources can be used to accelerate the discovery of 
proteins within signalling pathways that could be targeted by novel anticancer drugs, 
I have also been particularly cognisant of showing how mining big-data resources can 
be used to predict the drugs that would be most effective for the treatment of specific 
categories of patient tumours. My results firmly support the view that the time is ripe 
for integrative analyses of big data in computational system biology to yield 
revolutionary new treatments for diseases like cancer. 
5.2 Future Work  
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There is an urgent need to bridge the gap between advances in generating big 
biological datasets and our ability to integrate, analyse, and interpret these datasets. 
We could address many of these challenges by developing novel bioinformatics tools 
that would enable scientists that have little or no programming expertise to fully explore 
this data as effectively as our best-trained coder bioinformaticians. Soon, we aim to 
create a freely available web-based tool that will allow users to efficiently perform the 
various types of systems-levels analyses which I have showcased in this thesis. These 
will include: 1) performing functional enrichment analyses and visualising the results 
of these analyses. 2) the identification of regulatory kinases that are most likely the 
best drug targets within the signalling pathways/networks that are dysregulated in 
specific diseases or disease subtypes, 3) the definition of clinically relevant disease 
subtype classifications based on one or more different types of large-scale molecular 
dataset(s), and 4) the machine learning-based prediction of candidate drug 
compounds based on the similarity between primary patient tumours and cancer cell 
lines. We are optimistic that a user-friendly tool for experimental biologists will at least 
partially bridge the gap between our ability to generate large-scale datasets and 
extract biologically relevant insights from these. 
 
Our current regulatory network models unrealistically imply that the activation (or 
inhibition) of a regulatory kinase will, across different cell types, propagate a signal 
through the same cellular circuitry that will lead to the consistent activation of 
downstream kinases and transcription factors. Further, these models also 
unrealistically imply that the activation of a specific transcription factor will lead to the 
same changes in gene expression regardless of the cells in which they occur. In 
reality, however, we know that the dynamics of complex regulatory networks vary 
substantially between tissues and cell types [360–366], and there is, therefore, a vital 
need for the development of a tissue-specific interactome knowledgebase. In the near 
future, I intend to focus my efforts on addressing this pressing need in bioinformatics 
and system biology. Specifically, using healthy tissue and cell line-specific 
transcriptome profiles from the Genotype-Tissue Expression and the Human Protein 
Atlas projects and datasets from various other resources (such as those from the 
LINCS and Achilles projects), I aim to redefine kinase and transcription factor 
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interactions in a tissue-specific context. Concretely, for a given tissue type, I will 
leverage information from these projects to remove connections between genes 
and/or proteins from the global human interactome that are unsupported (i.e. 
interactions which do not seem to occur) in that specific tissue type. This will allow me 
to extract cell-type or tissue-specific subnetworks from the entire human interactome 
that will better represent the biology of different tissues and/or cell types. These 
subnetworks could then be applied to perform better informed regulatory network 
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Appendices  
Appendix A: Supplementary File Description  
Supplementary files for Chapter 3 
Supplementary file 1: Enrichment analyses of the KEGG pathways, Kinase 
Enrichment Analysis, and GO biological process results for the subtypes of pancreatic 
cancer obtained using the differentially expresses proteins, mRNA transcripts, and 
DNA methylation. 
 
Supplementary file 2: Differentially expressed mRNA transcripts, DNA methylation, 
proteins and miRNAs for the subtypes of pancreatic cancer.  
 
Supplementary file 3: Biomarker sets of mRNA transcripts, DNA methylation, 
proteins and miRNAs that each may be used to classify pancreatic cancer patients 
into the integrative (SNF) subtypes. 
 
Supplementary files for Chapter 4 
Supplementary file 1: Data of cancer studies and genomic alterations: The 
spreadsheet contains the following results according to the sheet name. TCGA Cancer 
Types; list and description of TCGA studies. GDSC Cancer Types; list and description 
of GDSC studies. Metabolic Pathways - First Tier; list of and description of first-tier 
Reactome metabolic pathways. GDSC vs TCGA Alterations; comparison between 
genomic alterations of GDSC cancer cell lines and TCGA cancers.  
 
Supplementary file 2: Dose-Response Differences. The spreadsheet contains the 
following results according to the sheet name. Pathway Drug Response Results; 
comparison of dose-responses of the HM and LM cell lines for all anticancer drugs 
that target the 24 signalling pathways and/or biological processes. 251 Drug 
comparisons; comparison of dose-responses of the HM and LM cell lines to each of 
the 251 anticancer drugs. 41 Sig Drug Results; 41 drugs that showed statistically 
significant differences in their dose-response comparisons between the HM and LM 
  79 
cancer cell lines. Within Cancer Efficacy Variation; results that show differences in log 
IC50 values between cancer cell lines of each cancer type with or without alterations 
to genes involved in each of the 16 first-tier metabolic pathways.  
 
Supplementary File 3: Differential Expression Results; list of statistically significantly 
differentially expressed genes between the HM and LM cancer supertypes. HM 
Supertype Upregulated Genes: list of upregulated genes in the HM tumours compared 
to the LM tumours. LM Supertype Upregulated Genes: list of upregulated genes in the 
LM tumours compared to the HM tumours. LM Supertype GO Mol Function; enriched 
gene ontology molecular function in the LM cancer supertypes.  HM Supertype GO 





















  80 
Appendix B:  
Table B-1: Key resources used in this thesis  
Resource Paper Source 
Software and Algorithms  
MATLAB N/A https://www.mathworks.com/products/matlab.html  
Python  N/A https://www.python.org  
R  N/A https://www.r-project.org  
Gene Set Enrichment Analysis [105] http://software.broadinstitute.org/gsea/index.jsp  
Cytoscape [165] https://cytoscape.org  
Enrichment Map [164] https://nrnb.org/tools/enrichmentmap.html 
yEd N/A https://www.yworks.com/products/yed 
PathVasio3 [167] https://www.pathvisio.org/ 
Expression2Kinases [168] http://www.maayanlab.net/X2K/ 
Kinase Enrichment Analysis [170] https://www.maayanlab.net/KEA2/ 
ChIP-x Enrichment Analysis [169] http://amp.pharm.mssm.edu/Enrichr/ 
Enrichr [175] http://amp.pharm.mssm.edu/Enrichr/ 
Co-occurring Mutated Driver Pathways [128] http://page.amss.ac.cn/shihua.zhang/software.html 
PARADIGM-Shift [139] https://github.com/ucscCancer/paradigm-scripts 
Tied Diffusion Through Interacting 
Event 
[138] https://github.com/epaull/TieDIE 
PathwayMapper [176] https://www.pathwaymapper.org/ 
Similarity Fusion Network [192] http://compbio.cs.toronto.edu/SNF/SNF/Software.html 
Big Data and Biological Knowledge Resources 
The Cancer Genome Atlas Data Portal  [8] https://portal.gdc.cancer.gov/ 
International Cancer Genomics 
Consortium Data Portal  
[9] https://dcc.icgc.org/ 
cBio Cancer Data Portal  [50] https://www.cbioportal.org/ 
Genomics of Drug Sensitivity in Cancer 
Database 
[5] https://www.cancerrxgene.org/ 
Uniprot Knowledgebase [36] https://www.uniprot.org/ 
KEGG Pathways Database [11] https://www.genome.jp/kegg/pathway.html 
Reactome Pathways Database [10,31] https://reactome.org/ 
WikiPathways Database [166] https://www.wikipathways.org/index.php/WikiPathways 
Kinase Enrichment Database [170] https://www.maayanlab.net/KEA2/ 
Molecular Signatures Database [163] http://software.broadinstitute.org/gsea/msigdb 
Sanger Consensus Cancer Gene 
Database 
[47] https://cancer.sanger.ac.uk/census 
Tumour Suppressor Gene Database [173] https://bioinfo.uth.edu/TSGene/ 
Oncogene Database [199] http://ongene.bioinfo-minzhao.org/ 
UCSC Super Pathway Database [253] https://github.com/ucscCancer/superpathway_db 
Cancer Cell Line Encyclopaedia  [6] https://portals.broadinstitute.org/ccle 
Gene Ontology Consortium [39] http://geneontology.org/ 
Pharos Knowledgebase [129] https://pharos.nih.gov/ 
BioGrid Database [368] https://thebiogrid.org/ 
ChEA Database  [169] http://amp.pharm.mssm.edu/Enrichr/ 
ClinicalTrail.gov [35] https://clinicaltrials.gov/ 
DrugBank [33] https://www.drugbank.ca/ 
 
 
 
 
